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ABSTRACT 
African trypanosomiasis is a neglected parasitic disease that is still of great public 
health relevance, and a severe impediment to agriculture in endemic areas. The 
pathogens possess certain unique metabolic features that can be exploited for the 
development of new drugs. Notably, they rely on an essential, mitochondrially-localized 
enzyme, Trypanosome Alternative Oxidase (TAO) for their energy metabolism, which 
is absent in the mammalian hosts and therefore an attractive target for the design of safe 
drugs. In this study, we cloned, expressed and purified the physiologically relevant form 
of TAO, which lacks the N-terminal 25 amino acid mitochondrial targeting sequence 
(∆MTS-TAO). A new class of 32 cationic and non-cationic 4-hydroxybenzoate and 4-
alkoxybenzaldehyde inhibitors was designed and synthesized, enabling the first 
structure-activity relationship studies on ∆MTS-TAO. Remarkably, we obtained 
compounds with enzyme inhibition values (IC50) as low as 2 nM, which were 
efficacious against wild type and multidrug-resistant strains of T. brucei and T. 
congolense. The inhibitors 13, 15, 16, 19, and 30, designed with a mitochondrion-
targeting lipophilic cation tail, displayed trypanocidal potencies comparable to the 
reference drugs pentamidine and diminazene, and showed no cross-resistance with the 
critical diamidine and melaminophenyl arsenical classes of trypanocides. The cationic 
inhibitors 15, 16, 19, 20, and 30 were also much more selective (900 - 344,000) over 
human cells than the non-targeted neutral derivatives (selectivity >8-fold). A 
preliminary in vivo study showed that modest doses of 15 and 16 reduced parasitemia of 
mice infected with T. b. rhodesiense (STIB900). These compounds represent a 
promising new class of potent and selective hits against African trypanosomes. 
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congolense 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
1. Introduction 
Alternative oxidases (AOXs), which are found across a broad range of organisms, 
including plants, nematodes, algae, yeast and certain disease–causing microorganisms 
including Trypanosoma spp., are mitochondrial, cyanide–insensitive, membrane-bound 
proteins that catalyse the oxidation of ubiquinol and the four-electron reduction of 
oxygen to water [1]. In T. brucei, a parasite that causes African trypanosomiasis in 
humans (sleeping sickness) [2] and in livestock (nagana) [3] throughout sub-Saharan 
Africa, the trypanosome alternative oxidase (TAO) is essential for the respiration of 
bloodstream form (BSF) parasites. In effect, in BSF trypanosomes, TAO is the sole 
terminal oxidase enzyme to re-oxidize the NADH that accumulates during glycolysis, 
and, as TAO has no counterpart in mammalian cells and is conserved among T. brucei 
subspecies [4], it has been validated as a promising target for the chemotherapy of 
African trypanosomiasis [5-7]. 
TAO is a cyanide-resistant and cytochrome-independent ubiquinol oxidase, formerly 
known as glycerol-3-phosphate oxidase, which is sensitive to the specific inhibitors 
salicylhydroxamic acid (SHAM) and ascofuranone (AF) [8-11]. Recently, we showed 
that dihydroxybenzoates and salicylhydroxamates could be efficiently targeted to the T. 
brucei mitochondrial matrix, by coupling them to a lipophilic cation [12]. A preliminary 
assessment of their antitrypanosomal activity found that some of these compounds 
appeared to inhibit TAO, which inspired the current strategy of synthesizing a small 
library of analogs optimized for (a) mitochondrial import and (b) TAO inhibition. As 
such, a series of 4-Hydroxybenzoate and 4-Alkoxybenzaldehyde derivatives was 
attached to triphenylphosphonium (TPP) and to quinolinium lipophilic cations, through 
linkers of variable length that would allow optimal engagement with the TAO binding 
pocket.  
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Another issue we addressed for the first time is that previous efforts to screen for, and 
optimize TAO inhibitors have used a non-physiological version of recombinant TAO 
that retains the N-terminal Mitochondrial Targeting Sequence (MTS) [13], despite its 
relatively poor stability and solubility, and its low yield [14]. The AOX gene of T. 
brucei contains 990 nucleotides, encoding the 330 amino acids full length protein, 
which includes the MTS. This sequence was predicted to be 25 amino acids long, using 
the computer program MITOPROT (http://www.expasy.org/tools/). As the MTS is 
cleaved off after transportation of the protein into the mitochondrion, physiologically 
functional and relevant form of TAO is lacking the MTS sequence [15]. 
Therefore, in the present study, we report for the first time the production of 
recombinant TAO enzyme in its more active, physiological state without the N-terminal 
MTS sequence (∆MTS-TAO). We also report the novel use of a SUMO expression 
system to optimize the production of this protein. The ∆MTS-TAO enzyme was used to 
study the activity of new TAO inhibitors based on the 4-hydroxybenzoate and 4-
alkoxybenzaldehyde scaffolds (Figure 1). These compounds were designed as analogues 
of lead compound 1, a low micromolar TAO inhibitor with potent activity against 
African trypanosomes [12]. The results of rTAO inhibition analysis, trypanocidal 
activity against wild type and several multi-drug-resistant strains of trypanosomes, and 
metabolic stability in mouse serum allowed the production of structure-activity 
relationships (SAR) with these potent TAO inhibitors and the identification of strong 
candidates for in vivo studies and preclinical development. This is the first time that not 
only the problem of local drug concentration is addressed as part of the inhibitor-design 
for a mitochondrial target in a protozoan parasite, but that it has been demonstrated that 
inhibitors coupled to such targeting moieties still inhibit the intended target without loss 
of affinity, and with greatly improved anti-parasite activity and selectivity index.
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Figure 1. Structure of the TAO inhibitors 
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2. Results 
2.1. Cloning and expression of Trypanosome Alternative Oxidase without 
mitochondrial targeting sequence (∆MTS-TAO) 
PCR amplification of ∆MTS-TAO and full length (fl) rTAO gave bands on agarose gel 
corresponding to 915 bp and 990 bp, respectively (Fig. S1A), while the PCR 
amplification of these TAO genes from the pET101-NHis6SUMO plasmid, i.e. products 
NHis6SUMO-∆MTS-TAO and NHis6SUMO-fl-TAO gave bands corresponding to 1.26 
kb and 1.34 kb, respectively (Fig. S1B). These PCR products were confirmed by 
sequence analysis to be the correct DNA fragments, and in the correct orientation. 
Plasmids with either the full-length or ∆MTS-TAO gene insert were used to transform a 
heme-deficient strain of E. coli, FN102, and the transformants were observed for its 
viability in the absence of aminolevulinic acid (ALA) in order to verify the ability of the 
two TAO constructs to complement the absence of terminal oxidase activity in this 
strain (Fig. 2SA and S2B). 
As expected, the result showed that terminal oxidase activity of the heme-deficient E. 
coli FN102 was restored in all native FN102 colonies having the NHis6SUMO-pET101 
plasmid with the TAO insert. There was no visible aerobic growth in the native FN102 
in the absence of ALA (Fig. S2A and S2B). 
It was also observed that cultures of colonies having the TAO insert plasmid plus 50 
µg/mL ALA displayed a better growth pattern than those having the TAO insert plasmid 
but without ALA and also better than the native FN102 cultures with 50 µg/mL ALA. 
This observation could be due to TAO restoring the terminal oxidase activities in the 
native FN102 cells but in addition increasing the total terminal oxidase activities in 
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native FN102 when the normal heme synthesis pathway was restored in the presence of 
ALA. 
However, there were no significant observable difference in the growth pattern of the 
FN102 E. coli expressing ∆MTS-TAO compared with clones expressing the fl-rTAO 
gene (Fig. S2A and S2B), showing that both forms are active as a terminal oxidase. This 
is consistent with our expectation that the MTS is cleaved off upon transportation into 
the mitochondria in trypanosomes and showed that this recombinant ∆MTS-TAO 
functioned as a terminal oxidase in the respiratory chain of the heme-deficient FN102 E. 
coli complementing the function of the deleted quinol oxidases. 
 
2.2. Purification of ∆MTS-TAO and fl-TAO. rTAO from various stages of 
purification was subjected to SDS-PAGE analysis. The crude FN102 lysate, a 
membrane fraction, flow-through, and peak fractions from a TALON column were 
subjected to discontinuous SDS PAGE (Fig. 2). As expected, a band corresponding to 
48 kD, which is the correct size for full length TAO (NHis6SUMO-fl-TAO), was 
observed in lanes 9 and 10 (duplicate). Removal of NHis6SUMO (11 kD) with the 
highly efficient SUMO (ULP-1) protease produced the native TAO protein with the 
expected 37 kD band corresponding to fl-rTAO (Fig. 2). Similarly, the 45 kD band 
corresponding to NHis6SUMO-∆MTS-TAO became 34 kD upon cleavage with ULP-1, 
corresponding to ∆MTS-TAO. Thus, a physiologically active TAO without 
Mitochondrial Targeting Signal was successfully purified. 
The purified ∆MTS-TAO obtained from the column was clear while that of the 
fl-TAO was slightly turbid; this may be because the MTS is known to be somewhat 
hydrophobic, reducing solubility. Although the two forms of purified TAO were both 
very active, the purified ∆MTS-TAO was found to be higher in total and specific 
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activity than fl-rTAO, and was obtained in higher yield (Table S1). Also, the purified 
∆MTS-TAO exhibited a superior purification (10.16-fold) than the fl-TAO (7.91-fold 
respectively).  
 
Figure 2. SDS-PAGE for the various purification steps involved in the purification of 
rTAO from FN102 E. coli. Purification process of ∆MTS-TAO and full length (fl) 
TAO. Lane: 1 = Marker protein (Bio-rad). 2 = Lysed FN102/ NHis6SUMO-∆MTS-
TAO cells. 3 = membrane fraction. 4 = NHis6SUMO-∆MTS-TAO. 6, 7, and 11 = 
∆MTS-TAO (NHis6SUMO is cleaved). 8 = Lysed FN102/NHis6SUMO-fl-TAO cells. 
10 = NHis6SUMO-fl-TAO. 5, 12, and 13 = fl-TAO (NHis6SUMO is cleaved). Three µg 
of protein was loaded onto each lane. 
 
2.3. Synthesis of the inhibitors 
The new cationic inhibitors (13, 15, 16, 19, and 20) derived from the 2,4-
hydroxybenzoate lead 1 [12] were synthesized in two steps (Scheme 1). The 
esterification of 33–36 with an equimolar amount of a dibromoalkane and sodium 
bicarbonate in acetonitrile gave a mixture of the bromoalkane intermediate (5, 6, 12, 14, 
17) and the dimer product (21, 26, 27). When dimethylformamide was used as solvent, 
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the formyl by-product (18) was also isolated from the reaction mixture by silica 
chromatography. The second step consisted in the nucleophilic substitution of the 
bromoalkane intermediate with either triphenylphosphine or quinoline to give the 
corresponding triphenylphosphonium (13, 15, 19) and quinolinium salts (16, 20), 
respectively. The synthesis of compounds 1–4, 7–11, and 22–25 was reported earlier 
[12].  
 
Scheme 1. Synthesis of 4-Hydroxybenzoate Derivativesa 
 
aReagents and conditions: (i) NaHCO3, CH3CN or DMF, ∆; (ii) Ph3P, CH3CN, 80 ºC, 
10 days; (iii) quinoline, CH3CN, 80 ºC, 10 days. 
 
The synthesis of the 2-hydroxybenzaldehyde derivatives 28–32 is shown in Scheme 2. 
Alkylation of 2,4-dihydroxybenzaldehyde with an equimolar amount of 1,14-dibromo 
tetradecane [16] and NaHCO3 (1 equivalent) in DMF yielded 28, 29 and 32 that were 
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isolated by silica chromatography. The cationic derivatives 30 and 31 were obtained by 
reaction of 28 with Ph3P and quinoline, respectively (Scheme 2).  
 
Scheme 2. Synthesis of 2-Hydroxybenzaldehyde Derivativesa 
 
aReagents and conditions: (i) NaHCO3, DMF, 65 ºC, 68 h (ii) Ph3P, CH3CN, 80 ºC, 10 
days; (iii) quinoline, CH3CN, 80 ºC, 10 days. 
 
2.4. Inhibition studies with ∆MTS-TAO and SAR of cationic and non-cationic 
inhibitors 
The compounds were tested as inhibitors of the ubiquinol oxidase activity of purified 
∆MTS-TAO by recording the absorbance change of ubiquinol-1 at 278 nm. 
Ascofuranone and SHAM were used as positive controls whereas DMSO was used as 
negative control. Control experiments were also carried out to check that no auto-
oxidation of ubiquinol-1 occurred in the medium. The quality of the purified rTAO was 
tested in the presence of up to 1 mM ascofuranone, which, at concentrations ≥0.1 µM 
completely inhibited the conversion of ubiquinol-1 to ubiquinone-1, indicating that no 
other oxidase was co-purified with TAO. To rule out any possibility that the inhibitors 
might act non-specifically as iron chelators (i.e. with other heme-containing proteins), 
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control experiments in the presence and absence of FeCl2 were performed, showing no 
difference in the extent of TAO inhibition. 
Most of the compounds tested against TAO (25 out of 30) displayed submicromolar 
inhibition. This represents a nearly 1000-fold increase in potency compared with the 
parent scaffolds 33–36 used to design the inhibitors (Table 1). Among these, one 
compound (18) displayed an IC50 value of 1.1 ± 0.2 nM, twice as potent as the reference 
drug ascofuranone, four inhibited TAO with IC50 < 10 nM (14, 17, 22, 23), and thirteen 
displayed two-digit nanomolar IC50 values. The 2,4-dihydroxybenzoates 1–11 inhibited 
TAO in the low nanomolar (non-cationic derivatives 5–11) to low micromolar range 
(cationic compounds 1–4). With the non-cationic derivatives, a correlation between 
inhibitory activity and methylene linker length was observed, the longest linkers giving 
the best, low nanomolar, inhibitors (C14 > C16 > C12 >> C10 > C6 > C4). For the C16 
linker, little difference in activity was observed when changing the R1 group from a 
bromine (9) to a formiate group (11). However, the introduction of a lipocation such as 
triphenylphosphonium (TPP) (2) or quinolinium (4) in this position was highly 
detrimental to TAO inhibition (>500-fold decrease in potency). As regards to cationic 
inhibitors, a linker with 14 methylene units was preferred (compare 1/2 and 3/4). Hence, 
this linker was chosen to design the rest of the inhibitors for the SAR studies. 
Importantly, for the 2-fluoro-4-hydroxybenzoate (13), 2,4-dihydroxy-6-
methylbenzoates (15, 16), and 4-hydroxy-2-methylbenzoates (19, 20), the addition of a 
mitochondrion-targeting lipocation in R1 barely affected their inhibitory potency against 
rTAO, showing that the lipocation does not participate in the interaction with the 
binding pocket (or, at the very least, does not interfere with binding to TAO) when a 
C14 linker is used.  
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Concerning the effect of modifications of the phenyl ring substituents R2 and R3 on 
rTAO inhibition, the introduction of a methyl group in R3 was favorable as shown by 
the 16- and 13-fold increase in inhibition of 15 and 16 compared to 1 and 3, 
respectively. In fact, the presence of a methyl group alone in R3 (i.e. without OH group 
in R2) was sufficient to get nanomolar range inhibitors (17–20) of similar potencies 
(compare 14/17, 15/19, 16/20) indicating that the 2-OH group is not essential for 
binding to TAO within this series. However, the presence of this 2-OH group should not 
be overlooked for the design of TAO inhibitors as it was essential to get superior 
metabolic stability in serum when combined with a 6-Me substituent (e.g. compounds 
15 and 16, discussed in section 7). Replacement of the R3 methyl group by a fluorine 
atom in the R2 position was favorable for the cationic TPP derivative (13 is 2.7-fold 
more potent than 19) whereas it was unfavorable for the non-cationic bromo analogue 
(12 is 4-fold less potent than 17).  
The 4-formyl-3-hydroxyphenoxy–based inhibitors 28–31 were somewhat less potent 
than the corresponding 4-hydroxybenzoate derivatives (compare 28 with 12/14/17, 29 
vs 18, and 30 vs 1/13/15/19) with the following order of inhibitory potency: R1 = Br > 
+PPh3 > OCHO >> quinolinium. Interestingly, the cationic TPP analogue 30 was 5-fold 
more potent than the quinolinium counterpart 31. 
The 4-hydroxybenzoate dimers (22–27) inhibited TAO in the low nanomolar range (11–
15.7 nM) whereas the 4-formyl-3-hydroxyphenoxy-based dimer 32 was approximately 
20-times less potent (IC50 = 240 nM) (Table 1). For the dimer series, a linker of 10 to 12 
methylene units seemed to be favored (compare 22/23 vs 24/25) whereas the nature of 
R1 and R2 was less influential (compare 24 with 26/27).  
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Table 1. Inhibition of purified rTAO
 
by 4-hydroxy benzoate (1–27), 4-alkoxy 
benzaldehyde (28–32), and 4-hydroxybenzoic acid derivatives (33–36). 
Cmpd Structure n R1 R2 R3 rTAO IC50a (µM) 
1 
 
14 +PPh3 - - 1.46 ±  0.01 
2 16 +PPh3 - - >5 
3 14 
 
- - 1.36 ± 0.06 
4 16 
 
- - >5 
5 4 Br - - 0.45 ± 0.01 
6 6 Br - - 0.24 ± 0.02 
7 12 Br - - 0.0174 ± 0.0018 
8 14 Br - - 0.0108 ± 0.0008 
9 16 Br - - 0.0124 ± 0.0003 
10 10  - - 0.150 ± 0.005 
11 16  - - 0.0144 ± 0.0012 
12 
 
 Br F H 0.030 ± 0.003 
13  +PPh3 F H 0.030 ± 0.003 
14  Br OH CH3 0.007 ± 0.001 
15  +PPh3 OH CH3 0.088 ± 0.013 
16  
 
OH CH3 0.104 ± 0.011 
17  Br H CH3 0.007 ± 0.003 
18  
 
H CH3 0.0011 ± 0.0002 
19  +PPh3 H CH3 0.081 ± 0.009 
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20  
 
H CH3 0.030 ± 0.005 
22 
 
10 - OH H 0.0069 ± 0.0001 
23 12 - OH H 0.0070 ± 0.0001 
24 14 - OH H 0.0157 ± 0.0013 
25 16 - OH H 0.0123 ± 0.0041 
27 14 - H CH3 0.013 ± 0.003 
28 
 
 Br - - 0.073 ± 0.011 
29  
 
- - 0.33 ± 0.02 
30  +PPh3 - - 0.22 ± 0.01 
31  
 
- - 1.23 ± 0.02 
32 
O
H
OH
O(CH2)14O
OHO
H
 
 - - - 0.24 ± 0.02 
33 
 
 - OH H 116 ± 11 
34  - F H 115 ± 5 
35  - CH3 OH 143 ± 6 
36  - CH3 H 112 ± 4 
AFb      0.0020 ± 0.0004 
SHAMc      5.93 ± 0.13 
a Purified recombinant trypanosome alternative oxidase from T. b. brucei (n = 3). 
bAscofuranone. c Salicylhydroxamic acid. 
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2.5. Kinetics and inhibitory mechanism of compounds on ∆MTS-TAO  
A set of 5 representative TAO inhibitors were selected for kinetic assays and to 
determine the type of inhibition with purified ∆MTS-TAO. The results were used to 
construct the Michaelis-Menten plots (Supplementary Fig. S3) which were transformed 
to Lineweaver–Burk plots. The Km and Vmax value for the uninhibited reaction was 
obtained as 384.3 ± 11.7 µM and 53.2 ± 6.6 µmol/min/mg, respectively, while the 
apparent Km () values for the inhibited reactions ranged from 464 to 1644 µM. The 
Ki values were obtained from secondary plots (slopes of reciprocal plots vs inhibitor 
concentrations) of the Lineweaver–Burk plots, the values were 71.4, 870, 4.1, 52.9, and 
34.1 nM for 11, 15, 18, 20, and 22, respectively. The Lineweaver–Burk analysis 
indicated that, similar to SHAM [17], compounds 11 and 22 inhibit TAO non-
competitively whereas compounds 15, 18, and 20 were competitive inhibitors (Figure 
3). It is notable that all the inhibitors that bound competitively were 2-methyl-4-
hydroxylbenzoates, whereas both compounds that produced a non-competitive plot 
lacked the 2-methyl group; this seems to indicate a somewhat different binding mode 
for the 2-methylbenzoates; the tail group, in contrast, does not seem to determine 
whether the binding mode is competitive or not. 
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Figure 3. Inhibitory mechanism of compounds on ∆MTS-TAO and determination of 
inhibitory constants Ki. Kinetic assays of TAO were carried out in the presence of 
varying amounts of compounds 11, 15, 18, 20, and 22. Lineweaver–Burk plots, 1/vo 
(µmol/min/mg protein)-1 vs 1/[ubiquinol] (µM)−1 revealed the inhibition mechanisms, 
and the secondary plots (insets), slopes of Lineweaver–Burk plots vs [inhibitor 
concentration] (µM) were used to estimate the of Ki for the inhibitors 11 (panel A), 22 
(B), 15 (C), 18 (D), and 20 (E). 
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2.6. In vitro activity against T. b. brucei and T. congolense wild type strains 
As TAO is essential for parasite viability, inhibition of TAO should inhibit parasite 
respiration and growth. Hence, the in vitro activities of the inhibitors were determined 
against wild type (WT) T. brucei and T. congolense, and against various drug-resistant 
T. brucei strains, using a resazurin-based assay (Tables 2–3). The cationic inhibitors 
were the most effective against T. brucei WT, with EC50 values ranging from 0.00058 
µM (13) to 1.75 µM (31). The TPP derivatives 15, 19, and 30, displaying single-digit 
nanomolar EC50 values, were between 13 and 87-fold more potent than their 
quinolinium counterparts 16, 20, and 31 in these whole-cell assays; similar ratios were 
seen against T. congolense. The 4-formyl-3-hydroxyphenoxy-based inhibitors (30, 31) 
were the least active of these series with EC50 of 0.13 and 1.75 µM, respectively, a 
result that correlated with a lower inhibitory action on ∆MTS-TAO (0.22 and 1.23 µM, 
respectively).  
The non-cationic TAO inhibitors displayed much lower activity against T. brucei, with 
EC50 values in the micromolar range. The formiate derivatives (11, 18, and 29) were 
approximately 3-times more potent than the bromo analogues (9, 17, and 28) whereas 
the dimer compounds (21–27, 32) were only weakly effective against T. brucei (IC50 > 
25 µM). These results were not unexpected as the compounds lack the mitochondrion-
targeting lipocation group, and the reduced activity probably results from poor 
accumulation in the mitochondrion of the parasite and possibly poor cellular penetration 
as well. The relatively low solubility of the dimeric compounds may also help explain 
the lack of in vitro activity against the parasite. 
Co-incubation with glycerol, which inhibits the T. brucei anaerobic ATP production 
pathway [18], significantly (P<0.05) potentiated the trypanocidal activities of most of 
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the compounds including SHAM, whereas it had no apparent effect on the efficacy of 
16, 18, 19, or on the effects of control drugs pentamidine and diminazene (Table 2). 
These results are consistent with the aerobic glycolytic pathway being affected by these 
compounds, which is expected for compounds inhibiting TAO. The anomalous results 
of compounds 16, 18 and 19, all 2-methyl-4-hydroxybenzoates, that were not enhanced 
in the presence of extracellular glycerol, may be due to a multi-target activity against T. 
brucei, making them less dependent than the other compounds on inhibition of TAO 
alone (see discussion). 
Cytotoxicity against human cells was low (CC50 > 200 µM) resulting in selectivity 
indices from > 8 (for non-cationic compounds) to between 110 and 344,000 for the 
cationic derivatives (15, 16, 19, 20, 30, and 31). 
The TAO inhibitors were consistently approximately 3-times less active against the T. 
congolense IL3000 strain than against T. brucei WT, but followed the same overall 
trends of inhibitor potency, and there was excellent correlation between the two sets of 
EC50 values (r2 = 0.95; Figure S4), showing that the compounds act on both species 
through a similar process. The systematic difference may be explained by a lesser 
degree of reliance on TAO by T. congolense, which is believed to have a slightly more 
complex mitochondrion than T. brucei. Nevertheless, three cationic TPP compounds 
(13, 15 and 19) were 5- to 40-fold more potent than the reference drug diminazene 
against this parasite species.  
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Table 2. EC50 values (µM) against Wild Type Strains of T. b. brucei, T. congolense, and Cytotoxicity against Human Cells 
(CC50, µM). 
Cmpd T. b. brucei WTa SIb 
 
T. b. brucei WT  
(+ 5 mM glycerol) 
RFc t-testd T. congolense WTe SIf Human cellsg 
5 NE, 400  NE, 400   ndh  >200 
6 17.7 ± 0.5 >11 12.1 ± 0.5 0.68 1.5E-3 72.9 ± 22.5 >2.7 >200 
7 14.5 ± 1.0 >27 6.2 ± 0.3 0.42 8.6E-4 52.1 ± 3.7 >7.7 >400i 
9 45.7 ± 1.5 >8 11.1 ± 0.7 0.24 8.6E-6 >100  >400i 
10 31.8 ± 0.9 >12 17.5 ± 0.9 0.55 1.2E-4 >100  >400i 
11 11.9 ± 1.6 >34 5.1 ± 0.5 0.43 2.5E-2 >100  >400i 
12 14.7 ± 0.1 >13 7.19 ± 0.07 0.49 1E-6 >50  >200 
13 0.00058 ± 0.00001 >344,000 0.00039 ± 0.00003 0.66 5.5E-3 0.018 ± 0.005 >11,000 >200 
14 14.6 ± 0.2 >13 7.71 ± 0.03 0.53 6E-6 >100  >200 
15 0.0016 ± 0.0005 >125,000 0.0014 ± 0.0001 0.92 8.1E-1 0.005 ± 0.001 >40,000 >200 
16 0.032 ± 0.0006 >6250 0.071 ± 0.002 2.22 2.1E-5 nd  >200 
17 14.4 ± 0.1 >13 7.5 ± 0.1 0.52 1E-6 nd  >200 
18 4.1 ± 0.1 >48 7.8 ± 0.4 1.92 7.5E-4 nd  >200 
19 0.0024 ± 0.0008 >83,000 0.0032 ± 0.0005 1.32 4.4E-1 0.039 ± 0.015 >5128 >200 
20 0.21 ± 0.02 >952 0.145 ± 0.007 0.69 5.6E-2 1.82 ± 0.45 >110 >200 
22 49.0 ± 7.8 >8 12.2 ± 0.6 0.25 1.5E-2 >100  >400i 
23 32.9 ± 0.9 >12 13.6 ± 1.2 0.41 4.0E-5 >100  >400i 
24 42.1 ± 2.9 >9 15.9 ± 1.5 0.38 7.5E-4 >100  >400i 
25 26.7 ± 5.5 >15 12.4 ± 0.3 0.46 8.0E-2 >100  >400i 
27 NE, 400  NE, 400   NE, 400  >200 
28 17.6 ± 0.5 >11 10.7 ± 0.5 0.61 8.8E-4 42.6 ± 6.3 >4.6 >200 
29 3.8 ± 0.1 >52 1.80 ± 0.01 0.48 7.2E-5 nd  >200 
30 0.133 ± 0.003 >1503 0.067 ± 0.005 0.51 4.8E-4 0.27 ± 0.12 >740 >200 
31 1.75 ± 0.01 >114 1.23 ± 0.08 0.70 2.6E-3 2.1 ± 0.7 >95 >200 
32 NE, 400  NE, 400   NE, 400  >200 
33j 17.1 ± 1.0  nd   nd 
 
nd 
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SHAMk 38.7 ± 4.8  7.0 ± 0.3 0.18 1.36E-11    
Pentamidine 0.0033 ± 0.0004  0.004 ± 0.0008 1.14 6.3E-1  
 
 
Diminazene 0.065 ± 0.007  0.063 ± 0.002 0.97 8.4E-1 0.20 ± 0.08    
PAOl 0.0011 ± 0.00003       0.29 ± 0.02 
aTrypomastigotes of T. b. brucei s427 (n ≥ 4). bSelectivity index (SI) = CC50/EC50 (T. brucei WT). cResistance factor relative to 
WT without glycerol: RF = EC50 (in the presence of glycerol)/EC50 (without glycerol). dUnpaired Student’s t-test comparing 
EC50 values against the WT strain in the presence and absence of 5 mM glycerol. eTrypomastigotes of T. congolense IL3000 
(n ≥ 2).  fSelectivity index (SI) = CC50/EC50 (T. congolense WT). gCytotoxicity on Human Foreskin Fibroblast (HFF) cells (n = 
2). hNot determined. iHuman embryonic kidney cells (n = 3). j2,4-Dihydroxybenzoic acid. kSalicylhydroxamic acid. 
lPhenylarsine oxide. Note: the MIC value for ascofuranone has been reported as 30 nM in the presence of glycerol and 250 µM 
under standard growth conditions [8].  
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Table 3. EC50 values (µM) against resistant strains of T. b. brucei. 
Cmpd T. b. brucei AQP2/3-ddKOa RF
b t-testc T. b. brucei AQP triple KOd RF
 t-test T. brucei B48e RF 
5 NE, 400   NE, 400   NE, 400  
6 11.6 ± 0.6 0.65 9.2E-4 12.1 ± 0.14 0.68 3.7E-4 20.5 ± 1.8 1.2 
7 10.0 ± 0.1 0.69 1.2E-2 4.7 ± 0.3 0.32 4.1E-4 14.9 ± 1.0 1.03 
9 14.5 ± 0.7 0.32 1.5E-5 5.1 ± 0.2 0.11 3.2E-6 49.0 ± 0.6 1.07 
10 27.4 ± 0.7 0.86 1.7E-2 15.6 ± 0.4 0.49 3.3E-5 22.1 ± 4.1 0.69 
11 5.0 ± 0.1 0.42 2E-2 1.27 ± 0.07 0.11 3E-3 13.0 ± 3.7 1.1 
12 6.8 ± 0.1 0.46 1E-6 7.0 ± 0.2 0.48 5E-6 17.3 ± 0.2 1.2 
13 0.00025 ± 0.00013 0.43 1.2E-2 0.00037 ± 0.00005 0.64 1.7E-2 0.00075 ± 0.00005 1.3 
14 7.30 ± 0.01 0.50 5E-6 6.8 ± 0.3 0.47 2.3E-5 15.6 ± 0.2 1.1 
15 0.0008 ± 0.0002 0.51 2.6E-1 0.0014 ± 0.0001 0.89 7.4E-1 0.0019 ± 0.0003 1.2 
16 0.035 ± 0.003 1.11 1.2E-1 0.03 ± 0.01 0.87 6.9E-1 0.089 ± 0.001 2.8 
17 7.1 ± 0.2 0.49 1E-6 7.2 ± 0.6 0.50 2E-4 14.4 ± 0.2 1.0 
18 1.40 ± 0.04 0.34 1.4E-5 1.8 ± 0.2 0.45 2.8E-4 4.44 ± 0.02 1.1 
19 0.0022 ± 0.0001 0.92 8.4E-1 0.005 ± 0.003 2.0 4.8E-1 0.0022 ± 0.0001 0.9 
20 0.10 ± 0.01 0.47 1.7E-2 0.086 ± 0.005 0.41 6.2E-3 0.30 ± 0.03 1.4 
22 24.6 ± 0.6 0.50 7E-2 7.1 ± 0.8 0.14 8E-3 41.6 ± 5.5 0.85 
23 26.7 ± 1.8 0.81 1.9E-2 8.9 ± 0.6 0.27 4.7E-6 33.6 ± 1.0 1.0 
24 28.2 ± 1.2 0.67 1.1E-2 14.8 ± 0.2 0.35 4.6E-4 36.6 ± 0.9 0.87 
25 14.3 ± 0.8 0.54 1.2E-1 9.3 ± 0.3 0.35 4.4E-2 31.9 ± 8.0 1.2 
27 NE, 400   NE, 400   NE, 400  
28 8.4 ± 0.2 0.48 8.5E-5 7.9 ± 0.4 0.45 1.4E-4 15.5 ± 0.8 0.9 
29 1.4 ± 0.1 0.38 5.6E-5 1.82 ± 0.02 0.48 8E-5 3.6 ± 0.2 1.0 
30 0.042 ± 0.005 0.32 6.1E-4 0.053 ± 0.006 0.40 3.6E-4 0.11 ± 0.02 0.8 
31 0.95 ± 0.03 0.54 4.7E-4 1.08 ± 0.03 0.62 2.4E-5 2.35 ± 0.15 1.3 
32 NE, 400   NE, 400   NE, 400  
33f nd   16.6 ± 0.9 0.96 4.4E-1 nd  
SHAMg 31.9 ± 0.9 0.82 3.6E-1 8.9 ± 0.4 0.23 4.3E-3 nd  
Pentamidine 0.047 ± 0.003 14.1 1E-4 0.064 ± 0.006 19.2 6E-4 0.94 ± 0.03 285 
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aT. brucei cell lines from which both aquaporins AQP2 and AQP3 have been knocked out. bResistance factor relative to WT. 
cUnpaired Student’s t-test comparing EC50 values against the WT strain. dT. brucei cell line from which all aquaporins were 
knocked out. eT. b. brucei strain resistant to pentamidine, diminazene, and melaminophenyl arsenicals. f2,4-Dihydroxybenzoic 
acid. gSalicylhydroxamic acid. hPhenylarsine oxide. 
 
  
 
Diminazene       0.78 ± 0.04 12 
PAOh 0.0013 ± 0.00004 1.17 2E-2 0.0013 ± 0.00003 1.11 4.4E-2   
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2.7. In vitro activity against T. brucei aquaglyceroporin-deficient strains 
Very little difference in activity was observed between WT and the multidrug resistant 
cell line B48 (resistant to diamidines including diminazene and pentamidine, some 
nucleoside analogues and to melaminophenyl arsenicals) [19, 20], with resistance 
factors (RF) consistently close to 1, whereas resistance to the control drugs diminazene 
and pentamidine was 12- and 285-fold respectively (Table 3). In contrast, most of the 
inhibitors were significantly more effective against the T. brucei cell lines from which 
both aquaporins AQP2 and AQP3 (AQP2/3-ddKO) [21] or all three T. brucei 
aquaporins were deleted (AQP1-3 triple KO) [22]. The effect of the compounds on the 
AQP knockout lines may be explained by a shift in metabolism of trypanosomes in the 
presence of the TAO inhibitors. Inhibition of TAO forces the parasite to produce large 
quantities of glycerol to survive anaerobically, producing ATP via glycerol kinase by 
substrate phosphorylation [23, 24]. In the absence of aquaglyceroporins, trypanosomes 
are not able to efficiently dispose of that glycerol resulting in the inhibition of the 
glycerol kinase and higher susceptibility to the TAO inhibitors. Indeed, the RF factors 
of EC50s in the presence of glycerol or in the absence of aquaporins were in close 
agreement (r2= 0.89 with two outliers of RF(glycerol) ~2). 
2.8. Metabolic stability of the inhibitors in mouse and horse sera 
The metabolic stability of five cationic benzoate derivatives (3, 13, 15, 16, 19, and 20) 
to esterases was assessed in mouse serum to assess the degree of in vivo hydrolysis of 
the ester bond over time. The stability of the 4-hydroxybenzaldehyde analogue (30), 
which cannot be metabolized by esterases, was also measured for comparison. The test 
compounds and the control drug were incubated at 37 ºC in mouse serum over a 24 h 
period and the quantity of compound recovered intact at different times (0.25, 0.5, 1, 2, 
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and 24 h) was quantified by HPLC–MS (Figure S5) [25]. The compounds resulting 
from the hydrolysis of the ester bond [i.e. benzoic acids 33–36, (14-
hydroxytetradecyl)triphenylphosphonium, and 1-(14-hydroxytetradecyl)quinolin-1-ium] 
were the only metabolites detected by HPLC–MS. 
The 2,4-dihydroxy-6-methyl benzoate derivatives (15, 16) were very stable in mouse 
serum with <20% hydrolysis after 24 h of incubation at 37 ºC (ditialzem: half-life
 
≈ 24 
h). In contrast, the 2-methyl-4-hydroxy derivatives (19, 20) were >99% hydrolyzed after 
24 h with an approximate half-life of 60 min and 30 min, respectively. This result was 
similar to the 2-hydroxy analogue 3, 50% of which was hydrolyzed after 1 h of 
incubation. The 2-fluoro analogue 13 was the most sensitive to esterases with a half-life 
<15 min. As expected, the 4-hydroxybenzaldehyde analogue (30), which has no ester 
bond, was not hydrolyzed in mouse serum (i.e. same amount recovered intact at t = 15 
min and t = 24 h). However, a large proportion of 30 was bound to serum proteins (≈ 
90%) as shown by the percentage of compound recovered intact after 15 min (12%) 
which was maintained steady over 24 h (Figure S5). This result may be related to Schiff 
base formation between the aldehyde group and the amino groups of the serum proteins.  
Some differences in the rate of metabolism were observed between mouse and horse 
sera. In an experiment with 2 time points (2 h, 24 h) performed with horse serum (data 
not shown), <30% of 15 and <40% of 16 were hydrolyzed after 24h of incubation 
whereas <20% of 19 was hydrolyzed after 2 h of incubation (compared with 
approximately 70% in mouse serum). Ditialzem was completely hydrolyzed after 24 h 
in this medium (1% recovered).  
2.9. Microsomal stability 
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Compounds 15 and 16 (5 µM) were exposed to human liver fractions, S9 fraction and 
human liver microsomes, to investigate in vitro microsomal stability. Both compounds 
were stable and did not suffer phase 1 metabolism with P450 enzymes/NADPH when 
compared with standard diclofenac (Table S2). Contrarily to 16, compound 15 did 
suffer phase 2 metabolism in presence of the S9 fraction and cofactor UDPGA with 
half-live of approximately 2 h. Altogether, these results suggest metabolic stability for 
these benzoate derivatives, confirming the observed in vivo stability in serum. 
2.10. Molecular Docking Studies. Predicted TAO binding modes 
Three bromo compounds, which only differ in the nature of the aromatic head (14, 17, 
28) were chosen to obtain information on the binding mode of the aromatic head 
without the interference of the tail substituent. Likewise, in order to study the influence 
of the tail on the TAO binding mode, three compounds with the same aromatic head 
(i.e. 2-methyl-4-hydroxybenzoate: 17, 19, 20) but different tails (i.e. bromine, TPP or 
quinolinium lipocations) were studied. Compound 5, with a short C4 linker was also 
studied for comparison.  
Compounds 5, 14, 17, 19, 20, and 28 were docked into the ubiquinol binding cavity of 
TAO using the coordinates of the TAO–AF2779OH complex [PDB ID code: 3VVA] 
[26]. AF2779OH (5-chloro-3-[(2E,6E)-8-hydroxy-3,7-dimethylnona-2,6-dienyl]-2,4-
dihydroxy-6-methylbenzaldehyde) is an ascofuranone (AF) derivative comprised of a 
substituted aromatic head and an isoprenoid tail but lacking the furanone ring. Similar 
to the structures of AF and its derivatives, the scaffold of the TAO inhibitors reported 
here consists of an aromatic head and a C14 methylene tail.  
The modelled structures revealed that analogs 14, 17, 19, 20, and 28 aligned perfectly at 
the head portion of AF2779-OH and, to a large extent, along their linkers. We observed 
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that the linker length was important for effective binding of the inhibitor into the 
enzyme cavity. The 14-methylene linker of all the inhibitors proved optimal for 
allowing the head portion access to the catalytic center (distance <5 Å). In contrast, the 
4-methylene linker of compound 5 was too short and resulted in reduced interactions 
with the hydrophobic region of the enzyme cavity, which may explain its lower 
inhibitory potency. In this predicted binding pattern, the inhibitors occupy the 
hydrophobic pocket of TAO close to the catalytic center via its head portion, while the 
tail extends outward into the solvent (Figure 4A,B). In addition to the hydrogen bond 
(HB) interactions of the carbonyl oxygen atom with the amino acids that form the active 
site (Arg96, Arg118 and Thr219), the 4-OH of the aromatic head of inhibitors 14, 17, 
19, and 20, and the aldehyde oxygen of 28 are in close proximity to the diiron center 
(Figure 4A,C-E); for compounds 17, 19, and 20 the methyl at position R3 is favored as it 
engages in hydrophobic interactions with a number of residues including Leu122, 
Ala216, and Thr219 (Figure 4C). For compound 14, the 2-OH group at position R3 
interacts via hydrogen bonding (HB) with Arg118 and Thr219 (Figure 4D). In contrast, 
no direct contact was revealed at the R2 position, where there seems to be opportunity 
for further derivatization (Figure 4C,D).  
As regards to the 2-hydroxybenzaldehyde derivative 28, its aromatic head binds TAO in 
a slightly different way: the aldehyde group engages in two HBs with Glu122 and 
Tyr220 whereas the 2-OH substituent forms one HB with Tyr220. In addition, it is 
noteworthy that the ether O atom of the molecule interacts with only one residue of the 
active site (HB with Arg118) in contrast to the benzoate derivatives, which carbonyl O 
atom engage in HBs with 3 residues of the active site (Figure 4E-F). These differences 
could possibly explain the 10-fold lower inhibition potency of the benzaldehyde 
derivatives compared with the 4-hydroxybenzoate inhibitors. 
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Figure 4. Modeled structure of derivatives 14 (R2 = CH3, R3 = OH), 17, 19, 20 (R2 = H, 
R3 = CH3), and 28 in the TAO active site. (A) Structural model of the TAO-inhibitors 
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complex. AH, ML, and LCT mean aromatic head, methylene linker (spacer), and 
lipocation tail, respectively. Compounds 14, 17, 19, 20 and 28 are shown in light pink, 
green, cyan, white, and orange stick models, respectively. The residues within 4 Å 
distance of the compounds are shown in ball-and-stick models. (B) Surface model of the 
TAO-inhibitors complex. Compounds 17, 19, and 20 are shown in green, cyan and 
white stick models, respectively. In the surface model, red and white show hydrophobic 
and hydrophilic regions, respectively. The tail region of the compounds is exposed to 
the solvent. (C) Close-up view of the active site for compound 17. The red and orange 
dashed lines are hydrogen bonds and hydrophobic interactions, respectively. (D) Close-
up view of the active site for compound 14 showing the hydrogen bonds (dashed lines) 
of the 2-OH (R3) and the carbonyl group with Arg96, Arg118, and Thr219. (E) Close-up 
view of the active site for compound 28. Hydrogen bonds appear as dashed lines. (F) 
Schematic drawing for the predicted interactions between the 4-hydroxybenzoate 
inhibitors (13, 14, 17, 19, 20) and TAO.  
 
3. Discussion 
The TAO gene contains 990 nucleotides, encoding a protein of 330 amino acids 
including the N-terminal 25 amino acid residue Mitochondrial Targeting Signal (MTS). 
For the majority of mitochondrial proteins, their transport into the mitochondria relies 
on two key fundamentals: (i) the presence of an MTS in the protein sequence and (ii) 
the presence of specific translocators in the mitochondrial membrane domain that 
recognize the specific signals [27]. Three main types of MTS have been found in 
proteins that are intended for delivery into the mitochondria: a stop-transfer or sorting 
signal, an internal signal, and N-terminal targeting sequence [28], which is an 
amphipathic helix of hydrophobic and basic amino acid residues that is usually cleaved 
after transportation of the protein to the mitochondria [15]. Consequently, the 
physiological and functional TAO is without MTS [27] but to date only the full length 
protein has been studied, despite problems of low stability, poor solubility and yield, 
and poor X-ray diffraction resolution of TAO crystals attributed to the MTS [26]. 
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Because the full length TAO is not the physiologically active form in BSF T. brucei, it 
is important to study ∆MTS-TAO instead, especially when designing inhibitors for 
potential therapeutic intervention.  
Here we report the first expression and purification of ∆MTS-TAO, and show 
that it was substantially more soluble, stable and active than fl-TAO, and could be 
purified at a higher yield. This ∆MTS-TAO enzyme was then used to characterize the 
inhibitory efficacy of 32 cationic and non-cationic compounds and develop structure-
activity relationships with these series of 4-hydroxybenzoate and 4-alkoxybenzaldehyde 
derivatives.  
We have previously reported the synthesis and characterization of 3 series of 
lipophilic cation (LC) conjugates based on SHAM and 2,4-DHBA scaffolds. These 
compounds were designed so as to efficiently target the mitochondrion of T. brucei, 
using either the flat heterocyclic 1-quinolinium cation or the bulky TPP cation as 
mitochondrion targeting moieties [12]. The findings from our previous report, providing 
a preliminary analysis of their structure-activity relationships (SAR), allowed the design 
and synthesis of the potent 4-hydroxybenzoate and 4-alkoxybenzaldehyde TAO 
inhibitors reported in the current paper. Similarly to the previously reported series [12], 
the presence of a mitochondrion-targeting lipophilic cation was essential to obtain 
nanomolar activity against trypanosomes. However, when this was included, the 
trypanocidal activity was very impressive, with several compounds displaying EC50 
values below that of the benchmark drug pentamidine, and 13 showing sub-nanomolar 
activity, while displaying no cross-resistance with the critical diamidine and 
melaminophenyl arsenical classes of trypanocides. Moreover, the compounds were 
similarly active, and displayed the same SAR, against T. brucei, whose subspecies T. b. 
gambiense and T. b. rhodesiense cause the human form of African sleeping sickness, 
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and T. congolense, the main pathogen of livestock in sub-Saharan Africa. For T. 
congolense, several compounds displayed activities much superior to the most-widely 
used drug, diminazene aceturate, with EC50 values up to 40-fold lower for 15, at 5 nM, 
and no observed toxicity on the control human cell line at concentrations up to 200 µM, 
as well as metabolic stability in serum. It is clear that the compounds here reported hold 
extraordinary promise for both human and animal trypanosomiasis. 
The presence of the lipocation hardly affected the inhibitory potency against 
TAO (4- to 10-fold), showing that the lipocation barely interferes with binding to TAO 
when a C14 linker is used. Although a strict correlation between EC50 against 
trypanosomes and inhibition of TAO was not observed, the measured IC50 values 
against ∆MTS-TAO are compatible with a mode of action via TAO inhibition.  
The higher susceptibility of the aquaporin-deficient T. brucei cell lines towards 
the test compounds (and SHAM) supports the hypothesis that these TAO inhibitors act 
on T. brucei through inhibition of TAO as designed, as the anaerobic pathway that is the 
cell’s only option for ATP-production when TAO is inhibited, produces intracellular 
glycerol in large quantities. In aquaporin-deficient trypanosomes, glycerol builds up in 
the cells, leading to the inhibition of glycerol kinase and the final route of ATP 
production [22]. The reason that the cells have to resort to the anaerobic production of 
glycerol upon inactivation of TAO is that the typical electron transport chain and 
oxidative phosphorylation present in mammalian cells are not operational in 
bloodstream form trypanosomes (BSFs). Consequently, the BSFs depend largely on 
glycolysis for its ATP generation. During aerobic respiration, BSFs produce a net of 
two molecules of ATP per glucose via glycolysis, which is dependent on the unique 
activity of TAO to regenerate NAD+. But when TAO is inhibited or during 
anaerobiosis, there is a metabolic shift in favor of glycerol production, aided by glycerol 
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kinase (GK) activity, producing a net of only one ATP from each glucose molecule 
consumed by the BSFs. Under these conditions, GK becomes critical for the survival of 
BSFs. The production of ATP by the trypanosome’s GK is via transphosphorylation of 
ADP with glycerol 3-phosphate (G3P) [24, 29, 30]. Therefore, co-administration of the 
TAO inhibitors and glycerol, or accumulation of glycerol in aquaporin-deficient T. 
brucei cell-lines, kills the parasites more effectively [31], as the glycerol competes with 
G3P, inhibiting the production of ATP by mass action [24]. 
However, as noted in sections 5 and 6, the trypanocidal activities of compounds 
16 (i.e. 2,4-dihydroxy-6-methyl benzoate derivative), 18 and 19 (i.e. 2-methyl-4-
hydroxybenzoates), were not enhanced in the presence of extracellular glycerol, and 
likewise the activities of 16 and 19 were not enhanced in the AQP knockout lines, 
although the activity of 18 was highly significantly enhanced against the AQP knockout 
lines. Of these, 18, in particular, is an excellent inhibitor of rTAO, although 16 and 19 
also display submicromolar IC50 values (Table 1). We conclude that some of the most 
potent 2(6)-methyl derivatives, particularly 16 and 19, display a multi-target activity 
against T. brucei, making them less dependent than the other compounds on inhibition 
of TAO alone; both compounds contain the cationic tail group that will make them 
accumulate strongly in the mitochondrion. In the case of compound 19, which shows a 
lower metabolic stability in serum (t1/2 ≈ 60 min), hydrolysis by cytosolic esterases to 
generate the much less active derivative 2-methyl-4-hydroxybenzoic acid (36: IC50 = 
111.6 µM) in addition to (14-hydroxytetradecyl)triphenylphosphonium metabolites, 
both poor inhibitors of TAO, could also explain the lower dependence of this compound 
on inhibition of TAO alone. Of interest, the glycerol sensitization was largest in the 
TAO inhibitor SHAM (5.5-fold; Table 2), similar to the EC50 shift in the AQP triple 
knockout (4.4-fold; Table 3). The less exclusive reliance on TAO inhibition by some of 
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the lipocation-coupled 2-methyl-4-hydroxybenzoates seems not to have increased 
toxicity to human cells, and would help prevent the development of drug resistance. 
The kinetics of our test compounds binding to TAO as determined by 
Lineweaver-Burk plot analysis indicated a non-competitive inhibition for the 2,4-
dihydroxybenzoate derivatives (11, 22), and a competitive inhibition for the 2-methyl-4-
hydroxy benzoates (15, 18, and 20). Interestingly, compounds 15, 18, and 20 with a C14 
linker were all competitive inhibitors, independently of the terminal tail group (i.e. TPP, 
formiate and quinolinium group, respectively), indicating that they interact with the 
TAO enzyme in a similar way. These data were supported by the docking experiments 
which showed that the 14-methylene linker was optimal for allowing the head portion 
access to the catalytic center. In contrast, the 2,4-dihydroxybenzoate derivatives with a 
C16 (formiate 11) and C10 linker (dimer 22) were noncompetitive inhibitors as shown 
by Lineweawer-Burk plot analysis. Crystallographic analysis is being attempted with 
representative compounds in order to resolve the exact binding modes of the two classes 
of inhibitors. Some of the inhibitors showed nanomolar IC50 values against ∆MTS-TAO 
in the same range as ascofuranone (IC50 = 2 nM; Table 1), which has also been reported 
to noncompetitively inhibit the ubiquinol-dependent O2 consumption of T. b. brucei (Ki 
= 2.38 nM) [32]. Similarly, SHAM was reported to inhibit TAO with a non-competitive 
(mixed type) mode of inhibition similar to the one reported here for compounds 11 and 
22 [23]. Such uncompetitive patterns were also observed by Clarkson and co-workers 
with different series of p-alkoxybenzhydroxamic acids, 3,4-dihydroxybenzoates, and N-
n-alkyl-3,4-dihydroxybenzamides having alkyl chains of 10 to 12 carbons [33].  
 The TAO inhibitors reported here are benzoate derivatives that are potentially 
prone to hydrolysis by esterases in vivo. However, the metabolism experiments showed 
that subtle changes in the structure allow control over the in vivo stability of the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 35
inhibitors in serum. From our results, it is clear that the substituents in the ortho position 
relative to the ester bond are crucial to modulate the sensitivity of the compounds to 
serum hydrolases. Increased stability was obtained for (2-OH, 6-Me) > 2-Me ≈ 2-OH 
>> 2-F. These modifications to the scaffold also improved the inhibitory potency 
against TAO by one order of magnitude [e.g. (2-OH,6-Me) ≈ 2-Me > 2-F >> 2-OH] and 
positively (13, 15, 16) or negatively (19, 20) affected the trypanocidal activity by 1- to 
3-fold with respect to the parent compounds 1 and 3. Hence, the 2,4-dihydroxy-6-
methyl TAO inhibitors 15 and 16, which are metabolically stable in serum and in 
microsomal fractions, and display single digit nanomolar trypanocidal activity and 
selectivity over human cells (SI > 6000), represent good candidates for in vivo studies in 
mouse models of trypanosomiasis. 
The activity of 15 and 16 against the human parasite T. b. rhodesiense STIB900 (IC50 = 
5 and 72 nM, respectively) was confirmed in vitro. Hence, a preliminary in vivo 
experiment in mice infected with T. b. rhodesiense STIB900/luc expressing the red-
shifted luciferase gene [34] showed that compounds 15 and 16 reduced the parasitemia 
by 95% 24 h after the last treatment (Table S3). Even though no cures were obtained at 
the modest dose tested (4×10 mg/kg ip), these promising results warrant further 
investigations with this class of compounds. 
 
4. Conclusion 
The reported procedure for the high yield expression of ∆MTS-TAO that is 
substantially more soluble, stable, and active, than fl-TAO is a helpful tool for the 
development of new TAO inhibitor drug candidates. We have successfully developed a 
class of potent and selective new hits active against human (T. brucei spp.) and 
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veterinary (T. congolense) African trypanosomes, and confirmed their designed mode of 
action as inhibition of TAO. This was accomplished by efficiently targeting the 
compounds to the trypanosome’s mitochondrion, thereby increasing the potency of the 
original small molecule inhibitors against T. brucei by up to 3 orders of magnitude. 
Importantly, the inhibitors with the 2,4-dihydroxy-6-methyl scaffold (e.g. 15, 16), which 
are metabolically stable in serum and in liver fractions, were active in the STIB900 
mouse model of acute infection and are promising candidates for further in vivo studies.  
 
5. Experimental section 
5.1. Chemistry. Anhydrous solvents were purchased to Aldrich/Fluka in SureSeal™ 
bottles and used as received. Thin Layer chromatography (TLC) was performed on 
silica gel 60 F254 aluminum TLC plates (MERCK). Medium pressure silica 
chromatography was performed on a FlashMaster Personal system using FlashPack SI 
prepacked columns (2, 5, 10, 20, and 50 g). Melting points were measured with a 
Reichert-Jung Thermovar apparatus and are uncorrected. LC-MS spectra were recorded 
on a WATERS apparatus integrated with a HPLC separation module (2695), PDA 
detector (2996) and Micromass ZQ spectrometer. Three different cone voltages were 
used (20, 40 and 60 ēV) and detection was in positive or negative mode (ES+ or ES-). 
Analytical HPLC was performed with a SunFire C18-3.5 µm column (4.6 mm × 50 
mm). Mobile phase A: CH3CN + 0.08% formic acid and B: H2O + 0.05% formic acid. 
UV detection was carried over 190 to 440 nm. 1H NMR and 13C NMR spectra were 
registered on a Bruker Avance-300, Varian Inova-400, Varian-Mercury-400, and 
Varian-system-500 spectrometers. Chemical shifts of the 1H NMR spectra were 
referenced to tetramethylsilane (δ 0) for CDCl3 or the residual proton resonance of the 
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deuterated solvents: DMSO-d6 (δ 2.50), CD3CN (δ 1.94), and CD3OD (δ 3.31). 
Chemical shifts of the 13C NMR spectra were referenced to CDCl3 (δ 77.16), DMSO-d6 
(δ 39.52), CD3CN (δ 1.32), and CD3OD (δ 49.0). Coupling constants J are expressed in 
hertz (Hz). Accurate mass was measured with an Agilent Technologies Q-TOF 6520 
spectrometer using electrospray ionization. All of the biologically tested compounds 
were ≥ 95% pure by HPLC. 
5.1.1. General procedure for the synthesis of the bromoalkane intermediates (5, 6, 
12, 14, 17, 28) and dimers (21, 26, 27, 32). A Kimax tube was charged with an 
equimolar quantity of benzoic acid 33–37 (1.3 mmol, 1 equiv.), sodium bicarbonate (1.3 
mmol, 1 equiv), and the dibromoalkane (1.3 mmol, 1 equiv.) in anhydrous acetonitrile 
or DMF (10 mL). The tube was flushed with argon, stopped, and the reaction mixture 
was stirred at 65 ºC or 90 ºC for the time indicated in each case. The solvent was 
evaporated under vacuum to give a crude solid residue. The different products were 
isolated by silica chromatography (5g SI prepacked column) using hexane/EtOAc 
(100/0 → 50/50) as eluent. The structure of the obtained isomer (i.e. the benzoate 
product and not the 4-alkyloxy-substituted benzoic acid isomer) was checked by 1H–13C 
HMBC and NOESY experiments. 
4-Bromobutyl 2,4-dihydroxybenzoate (5). Following the general procedure 5.1.1. 
starting from 1,4-dibromobutane (0.305 g, 1.95 mmol) and using CH3CN as solvent (20 
mL). The reaction mixture was heated at 65 ºC for 66 h. Compound 5 was isolated by 
silica chromatography using hexane/EtOAc (98/2) as eluent. White solid (202 mg, 
36%). HPLC (UV): 100%. 1H NMR (300 MHz, CDCl3) δ 10.94 (s, 1H), 7.66 (d, J = 8.4 
Hz, 1H), 6.38 – 6.24 (m, 2H), 5.63 (br s, 1H), 4.28 (t, J = 6.0 Hz, 2H), 3.41 (t, J = 6.2 
Hz, 2H), 2.04 – 1.80 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 170.0, 163.8, 162.1, 132.0, 
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108.0, 106.0, 103.3, 64.2, 33.2, 29.4, 27.4. LRMS (ES+) m/z 289 (M+H)+. HRMS (ESI+) 
m/z 287.9988 (C11H13BrO4 requires 287.9997).  
6-Bromohexyl 2,4-dihydroxybenzoate (6). Following the general procedure 5.1.1. 
starting from 1,6-dibromohexane (300 mg, 1.95 mmol) and using CH3CN as solvent (20 
mL). The reaction mixture was heated at 65 ºC for 4 days. Compounds 6 and 21 were 
isolated by silica chromatography using hexane/EtOAc as eluent. Compound 6 eluted 
with hexane/EtOAc:90/10 and 21 with hexane/EtOAc:75/25. Compound 6: yellowish 
oil (203 mg, 25%); HPLC (UV) > 95 %. 1H NMR (300 MHz, CDCl3) δ 11.06 (s, 1H), 
7.73 (dd, J = 8.6 Hz, 1H), 6.39 (dd, J = 2.5, 8.6 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 5.40 
(s, 1H), 4.32 (t, J = 6.5 Hz, 2H), 3.42 (t, J = 6.7 Hz, 2H), 2.00 – 1.65 (m, 4H), 1.61 – 
1.37 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 170.2, 163.7, 161.9, 132.0, 108.0, 106.1, 
103.3, 65.1, 33.9, 32.7, 28.6, 27.9, 25.4. LRMS (ESI+) m/z 317, 319 (M+H)+. HRMS 
(ESI+) m/z 316.0315 (C13H17BrO4 requires 316.0310). 
14-Bromotetradecyl 2-fluoro-4-hydroxybenzoate (12). Following the general 
procedure 5.1.1. starting from 1,14-dibrotetradecane (67 mg, 0.19 mmol) and using 
CH3CN as solvent (20 mL). The reaction mixture was heated at 90 ºC for 22 days. 
Compound 12 was isolated by preparative plate chromatography on silica using 
hexane/EtOAc (8/2) as eluent. Beige solid (16 mg, 20%); mp 42 – 48 ºC. HPLC (UV) > 
95 %. 1H NMR (300 MHz, CDCl3) δ 10.95 (s, 1H), 7.66 (d, J = 9.5 Hz, 1H), 6.46 – 6.19 
(m, 2H), 4.24 (t, J = 6.5 Hz, 1H), 3.91 (t, J = 6.4 Hz, 1H), 3.35 (t, J = 6.6 Hz, 2H), 1.97 
– 0.57 (m, 24H). 13C NMR (75 MHz, CDCl3) δ 170.2, 165.2, 164.0, 131.3, 108.0, 105.6, 
101.3, 68.1, 33.9, 33.8, 32.8, 32.7, 29.0, 28.01, 27.96, 25.4. LRMS (ESI+) m/z 431, 433 
(M+H)+. HRMS (ESI+) m/z 430.1516 (C21H32BrFO3 requires 430.1519). 
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14-Bromotetradecyl 2,4-dihydroxy-6-methylbenzoate (14). Following the general 
procedure 5.1.1. starting from 1,14-dibrotetradecane (530 mg, 1.49 mmol) and using 
CH3CN as solvent (15 mL). The reaction mixture was heated at 90 ºC for 48 h. The 
products were isolated by silica chromatography. Compound 14 eluted with 
hexane/EtOAc:95/5 and 26 with hexane/EtOAc:85/15. Compound 14: colorless solid 
(155 mg, 26%); mp 62.5 – 64.7 ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, CDCl3) δ 
11.84 (s, 1H), 6.21 (d, J = 2.8 Hz, 1H), 6.16 (d, J = 2.8 Hz, 1H), 5.53 (brs, 1H), 4.26 (t, 
J = 6.5 Hz, 2H), 3.34 (t, J = 6.8 Hz, 2H), 2.43 (s, 3H), 1.93 – 1.67 (m, 4H), 1.52 – 1.14 
(m, 20H). 13C NMR (75 MHz, CDCl3) δ 172.0, 165.5, 160.3, 144.1, 111.4, 106.0, 101.4, 
65.7, 34.2, 33.0, 29.72, 29.66, 29.61, 29.57, 29.3, 28.9, 28.7, 28.3, 26.3, 24.6. LRMS 
(ESI+) m/z 443, 445 (M+H)+. HRMS (ESI+) m/z 442.1709 (C22H35BrO4 requires 
442.1719).
 
14-Bromotetradecyl 4-hydroxy-2-methylbenzoate (17). Following the general 
procedure 5.1.1. starting from 1,14-dibrotetradecane (470 mg, 1.32 mmol) and using 
DMF as solvent (10 mL). The reaction mixture was heated at 65 ºC for 68 h. The 
products were isolated by silica chromatography. Compounds 17 and 27 eluted with 
hexane/EtOAc:90/10, and 18 with hexane/EtOAc:80/20. Compound 17: colorless solid 
(41 mg, 7%); mp 54.4 – 57.3 ºC. HPLC (UV) > 95 %. 1H NMR (400 MHz, CDCl3) δ 
7.82 (d, J = 9.3 Hz, 1H), 6.66 – 6.60 (m, 2H), 5.55 (br, 1H), 4.19 (t, J = 6.7 Hz, 2H), 
3.33 (t, J = 6.9 Hz, 2H), 2.50 (s, 3H), 1.78 (p, J = 7.0 Hz, 2H), 1.66 (h, J = 7.1 Hz, 2H), 
1.4 – 1.1 (m, 20H). 13C NMR (100 MHz, CDCl3) δ 167.6, 158.8, 143.5, 133.4, 122.3, 
118.5, 112.8, 64.9, 34.2, 33.0, 29.9, 29.74, 29.70, 29.67, 29.66, 29.58, 29.4, 28.9, 28.3, 
26.3, 22.4. LRMS (ESI+) m/z 427, 429 (M+H)+. HRMS (ESI+) m/z 426.1790 
(C22H35BrO3 requires 426.1770). 
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14-(Formyloxy)tetradecyl 4-hydroxy-2-methylbenzoate (18). Yellowish solid (31 
mg, 6%); mp 59.0 – 60.5 ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, CDCl3) δ 8.00 
(s, 1H), 7.86 – 7.75 (m, 1H), 6.66 – 6.60 (m, 2H), 6.36 (br s, 1H), 4.18 (t, J = 6.5 Hz, 
2H), 4.10 (t, J = 6.6 Hz, 2H), 2.49 (s, 3H), 1.70 – 1.53 (m, 4H), 1.34 – 1.15 (m, 20H). 
13C NMR (75 MHz, CDCl3) δ 167.8, 161.7, 159.2, 143.4, 133.4, 122.0, 118.5, 112.8, 
65.0, 64.5, 29.8, 29.7, 29.64, 29.61, 29.5, 29.37, 29.28, 28.9, 28.6, 26.4, 26.3, 25.9, 
22.4. LRMS (ESI+) m/z 393 (M+H)+. HRMS (ESI+) m/z 392.2548 (C23H36O5 requires 
392.2563). 
Hexane-1,6-diyl bis(2,4-dihydroxybenzoate) (21). Colorless solid (5.8 mg, 0.7%); mp 
68 – 80 ºC. HPLC (UV) > 91 %. 1H NMR (300 MHz, CDCl3+CD3OD) δ 7.61 (d, J = 
9.4 Hz, 2H), 6.46 – 6.00 (m, 4H), 4.83 (br s, 2H), 4.24 (t, J = 6.5 Hz, 4H), 1.73 (t, J = 
6.6 Hz, 4H), 1.58 – 1.31 (m, 4H). 13C NMR (75 MHz, CDCl3+CD3OD) δ 170.2, 163.8, 
163.4, 131.7, 108.3, 104.9, 102.7, 64.8, 28.6, 25.8. LRMS (ESI+) m/z 391 (M+H)+. 
HRMS (ESI+) m/z 390.1296 (C20H22O8 requires 390.1315). 
Tetradecane-1,14-diyl bis(2,4-dihydroxy-6-methylbenzoate) (26). Colorless solid 
(29.6 mg, 5%); HPLC (UV) = 87%. 1H NMR (300 MHz, DMSO-d6) δ 10.90 (br s, 2H), 
10.02 (br s, 2H), 6.25 – 6.06 (m, 4H), 4.22 (t, J = 6.5 Hz, 4H), 2.30 (s, 6H), 1.73 – 1.58 
(m, 4H), 1.46 – 1.16 (m, 20H). 13C NMR (75 MHz, CDCl3+ CD3OD) δ 170.2, 161.8, 
161.3, 141.1, 110.5, 107.0, 100.5, 64.8, 29.05, 28.97, 28.6, 28.1, 25.6, 22.5, 21.3. 
LRMS (ESI+) m/z 531 (M+H)+. HRMS (ESI+) m/z 530.2874 (C30H42O8 requires 
530.2880). 
 
Tetradecane-1,14-diyl bis(4-hydroxy-2-methylbenzoate) (27). Colorless solid (15 
mg, 6.6%); mp 42 – 46 ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, CD3OD) δ 7.82 
(d, J = 9.3 Hz, 2H), 6.74 (m, 2H), 6.64 (d, J = 6.6 Hz, 2H), 4.21 (t, J = 6.5 Hz, 4H), 2.51 
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(s, 6H), 1.73 (t, J = 7.1 Hz, 4H), 1.49 – 1.03 (m, 20H). 13C NMR (75 MHz, CD3OD) δ 
168.8, 161.5, 143.8, 133.9, 121.3, 118.9, 113.3, 65.3, 30.3, 30.22, 30.20, 29.9, 29.4, 
26.8, 22.6. LRMS (ESI+) m/z 499 (M+H)+. HRMS (ESI+) m/z 498.2995 (C30H42O6 
requires 498.2981).
 
4-((14-Bromotetradecyl)oxy)-2-hydroxybenzaldehyde (28). Following the general 
procedure 5.1.1. starting from 1,14-dibrotetradecane (385 mg, 1.1 mmol) and using 
DMF as solvent (10 mL). The reaction mixture was stirred at 65 ºC for 24 h, and 68 h at 
room temperature. The products 28, 29 and 32 were isolated by silica chromatography 
using hexane/EtOAc:97/3. Compound 28: colorless solid (17 mg, 4%); mp 55.5 – 58.6 
ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, CDCl3) δ 11.41 (s, 1H), 9.64 (s, 1H), 7.35 
(d, J = 8.6 Hz, 1H), 6.46 (dd, J = 2.4, 8.6 Hz, 1H), 6.34 (d, J = 2.4 Hz, 1H), 3.93 (t, J = 
6.6 Hz, 2H), 3.34 (t, J = 6.9 Hz, 2H), 1.82 – 1.69 (m, 4H), 1.23 (m, 20H). 13C NMR (75 
MHz, CDCl3) δ 194.4, 166.6, 164.7, 135.3, 115.2, 108.9, 101.2, 68.8, 34.2, 33.0, 29.9, 
29.74, 29.68, 29.6, 29.5, 29.1, 28.9, 28.3, 26.1. LRMS (ESI+) m/z 413, 415 (M+H)+. 
HRMS (ESI+) m/z 412.1621 (C21H33BrO3 requires 412.1613). 
14-(4-Formyl-3-hydroxyphenoxy)tetradecyl formate (29). Yellowish solid (40 mg, 
9%); mp 63.5 – 68.8 ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, CDCl3) δ 11.41 (s, 
1H), 9.63 (s, 1H), 7.99 (s, 1H), 7.34 (d, J = 8.7 Hz, 1H), 6.45 (dd, J = 2.4, 8.7 Hz, 1H), 
6.34 (d, J = 2.4 Hz, 1H), 4.09 (t, J = 7.1 Hz, 2H), 3.93 (t, J = 6.5 Hz, 2H), 1.82 – 1.04 
(m, 24H). 13C NMR (75 MHz, CDCl3) δ 194.4, 166.6, 164.7, 161.4, 135.3, 115.1, 108.9, 
101.2, 68.7, 64.3, 29.84, 29.69, 29.68, 29.63, 29.4, 29.3, 29.1, 28.64, 28.57, 26.1, 26.0. 
LRMS (ESI+) m/z 379 (M+H)+. HRMS (ESI+) m/z 378.2417 (C22H34O5 requires 
378.2406).
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 42
4,4'-(Tetradecane-1,14-diylbis(oxy))bis(2-hydroxybenzaldehyde) (32). Colorless 
solid (12 mg, 3%); mp 111 – 112.8 ºC. HPLC (UV) > 95 %. 1H NMR (300 MHz, 
CDCl3) δ 11.46 (s, 2H), 9.69 (s, 2H), 7.40 (d, J = 8.7 Hz, 2H), 6.51 (dd, J = 2.4, 8.7 Hz, 
2H), 6.39 (d, J = 2.4 Hz, 2H), 3.98 (t, J = 6.6 Hz, 4H), 1.83 – 1.20 (m, 24H). 13C NMR 
(75 MHz, CDCl3) δ 194.4, 166.6, 164.7, 135.3, 115.2, 108.9, 101.2, 68.8, 29.8, 29.77, 
29.71, 29.5, 29.1, 26.1. LRMS (ESI+) m/z 471 (M+H)+. HRMS (ESI+) m/z 470.2667 
(C28H38O6 requires 470.2668). 
5.1.2. General procedure for the synthesis of the triphenylphosphonium (13, 15, 19, 
30) and quinolinium salts (16, 20, 31). A Kimax tube was charged with an equimolar 
amount of the bromoalkane derivative (5, 6, 12, 14, 17, 28; ≈30 mg, 1 equiv.) and 
triphenylphosphine (procedure 5.1.2.1) or quinoline (procedure 5.1.2.2) in anhydrous 
acetonitrile (0.5 mL). The tube was flushed with argon, stopped and the reaction 
mixture was stirred at 80 ºC for several days. The products were purified by 
recrystallization as described below.  
 (14-((2-Fluoro-4-hydroxybenzoyl)oxy)tetradecyl)triphenylphosphonium bromide 
(13). Following the general procedure 5.1.2.1 the reaction mixture was heated at 80 ºC 
for 7 days. The solvent was removed under vacuum and 13 was obtained as brown solid 
(18 mg, 86%) by recrystallization from CH2Cl2/hexane. HPLC (UV) > 95 %. 1H NMR 
(400 MHz, CD3OD) δ 7.85 – 7.72 (m, 16H), 6.64 (dd, J = 2.4, 8.7 Hz, 1H), 6.54 (dd, J = 
2.4, 12.9 Hz, 1H), 4.26 (t, J = 6.5 Hz, 2H), 3.44 – 3.33 (m, 2H), 1.80 – 1.60 (m, 4H), 
1.54 (p, J = 7.0 Hz, 2H), 1.49 – 1.21 (m, 18H). 13C NMR (101 MHz, CD3OD) δ 166.0 
(d, J = 3.8 Hz), 165.1 (d, J = 12.2 Hz), 165.0 (d, J = 258 Hz), 136.3 (d, J = 3.1 Hz), 
134.8 (d, J = 10.0 Hz), 134.5 (d, J = 2.7 Hz), 131.5 (d, J = 12.7 Hz), 120.0 (d, J = 86.3 
Hz), 112.6 (d, J = 2.7 Hz), 110.7, 104.5 (d, J = 24.7 Hz), 65.9, 31.6 (d, J = 16.1 Hz), 
30.6, 30.58, 30.52, 30.47, 30.3 (d, J = 12.5 Hz), 29.8, 29.7, 27.0, 23.5 (d, J = 4.5 Hz), 
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22.7 (d, J = 50.8 Hz). LRMS (ESI+) m/z 613 (M)+. HRMS (ESI+) m/z 613.3243 
(C39H47FO3P requires 613.3247). 
(14-((2,4-Dihydroxy-6-methylbenzoyl)oxy)tetradecyl)triphenylphosphonium 
bromide (15). Following the general procedure 5.1.2.1 the reaction mixture was heated 
at 80 ºC for 12 days. The solvent was removed under vacuum and 15 was obtained as 
colorless solid (42.6 mg, 97%) by recrystallization from CH2Cl2/hexane; mp 128 – 129 
ºC. HPLC (UV) > 95 %. 1H NMR (500 MHz, CD3OD) δ 7.89 (td, J = 1.8, 7.2 Hz, 3H), 
7.83 – 7.72 (m, 12H), 6.19 (d, J = 2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 4.33 (t, J = 6.5 
Hz, 2H), 3.42 – 3.34 (m, 2H), 2.46 (s, 3H), 1.82 – 1.73 (m, 2H), 1.66 (h, J = 8.0 Hz, 
2H), 1.54 (p, J = 7.3 Hz, 2H), 1.50 – 1.42 (m, 2H), 1.42 – 1.22 (m, 16H). 13C NMR (75 
MHz, CD3OD) δ 173.1, 166.3, 163.7, 144.4, 136.3 (d, J = 3.6 Hz), 134.8 (d, J = 10.1 
Hz), 131.5 (d, J = 12.7 Hz), 120.0 (d, J = 86.2 Hz), 112.5, 105.8, 101.8, 66.3, 31.6 (d, J 
= 15.7 Hz), 30.62, 30.57, 30.5, 30.4, 30.3, 30.2, 29.9, 29.7, 27.2, 24.5, 23.5 (d, J = 4.4 
Hz), 22.7 (d, J = 51.0 Hz). LRMS (ESI+) m/z 625 (M)+. HRMS (ESI+) m/z 625.3465 
(C40H50O4P requires 625.3447).  
1-(14-((2,4-Dihydroxy-6-methylbenzoyl)oxy)tetradecyl)quinolin-1-ium bromide 
(16). Following the general procedure 5.1.2.2 the reaction mixture was heated at 80 ºC 
for 12 days. The precipitate was collected by filtration and rinsed with cold CH3CN to 
give 16 as brown solid (19.5 mg, 57%); mp 167 – 168 ºC. HPLC (UV) > 95 %. 1H 
NMR (300 MHz, CD3OD) δ 9.40 (d, J = 6.0 Hz, 1H), 9.19 (d, J = 8.4 Hz, 1H), 8.52 (d, 
J = 9.0 Hz, 1H), 8.42 (dd, J = 1.5, 8.6 Hz, 1H), 8.35 – 8.23 (m, 1H), 8.07 (td, J = 6.5, 
9.4, 10.1 Hz, 2H), 6.22 – 6.08 (m, 2H), 5.07 (t, J = 7.7 Hz, 2H), 4.31 (t, J = 6.5 Hz, 2H), 
2.46 (s, 3H), 1.75 (q, J = 6.9 Hz, 2H), 1.52 – 1.13 (m, 22H). 13C NMR (75 MHz, 
CD3OD) δ 172.9, 166.1, 163.4, 150.0, 148.9, 144.3, 137.3, 132.1, 131.6, 131.3, 122.9, 
119.4, 112.4, 101.6, 66.1, 59.3, 31.0, 30.8, 30.41, 30.37, 30.34, 30.3 (m), 30.0, 29.5, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 44
27.3, 27.0, 24.6, 24.2. LRMS (ESI+) m/z 492 (M)+. HRMS (ESI+) m/z 492.3128 
(C31H42NO4 requires 492.3114). 
(14-((4-Hydroxy-2-methylbenzoyl)oxy)tetradecyl)triphenylphosphonium bromide 
(19). Following the general procedure 5.1.2.1 the reaction mixture was heated at 80 ºC 
for 10 days. The solvent was removed under vacuum and 19 was obtained as beige 
hygroscopic solid (35 mg, 82%) by recrystallization from CH2Cl2/hexane. HPLC (UV) 
> 95 %. 1H NMR (500 MHz, CD3OD) δ 7.89 (td, J = 1.8, 7.1 Hz, 3H), 7.78 (m, 16H), 
6.65 (d, J = 2.5 Hz, 1H), 6.64 – 6.61 (m, 1H), 4.23 (t, J = 6.5 Hz, 2H), 3.44 – 3.34 (m, 
2H), 2.51 (s, 3H), 1.74 (p, J = 6.7 Hz, 2H), 1.66 (h, J = 8.1 Hz, 2H), 1.54 (p, J = 7.2 Hz, 
2H), 1.48 – 1.40 (m, 2H), 1.40 – 1.22 (m, 16H). 13C NMR (75 MHz, CD3OD) δ 168.9, 
162.3, 144.1, 136.2 (d, J = 3.4 Hz), 134.8 (d, J = 9.9 Hz), 134.1, 131.5 (d, J = 12.7 Hz), 
121.6, 120.0 (d, J = 86.2 Hz), 119.2, 113.7, 65.5, 31.6 (d, J = 16 Hz), 30.71, 30.61, 
30.55, 30.50, 30.4, 30.3, 29.9, 29.8, 27.2, 24.2, 23.5 (d, J = 4.5 Hz), 22.7 (d, J = 51 Hz), 
22.5. LRMS (ESI+) m/z 609 (M)+. HRMS (ESI+) m/z 609.3499 (C40H50O3P requires 
609.3498). 
1-(14-((4-Hydroxy-2-methylbenzoyl)oxy)tetradecyl)quinolin-1-ium bromide (20). 
Following the general procedure 5.1.2.2 the reaction mixture was heated at 80 ºC for 10 
days. The precipitate was collected by filtration and rinsed with cold CH3CN to give 20 
as brown solid (21 mg, 63%); mp 145 – 146 ºC. HPLC (UV) > 95 %. 1H NMR (300 
MHz, CD3OD) δ 9.43 (d, J = 5.8 Hz, 1H), 9.21 (d, J = 8.4 Hz, 1H), 8.55 (d, J = 9.0 Hz, 
1H), 8.44 (dd, J = 1.5, 8.1 Hz, 1H), 8.30 (ddd, J = 1.6, 6.9, 8.8 Hz, 1H), 8.19 – 7.98 (m, 
2H), 7.80 (d, J = 8.5 Hz, 1H), 6.68 – 6.56 (m, 2H), 5.09 (t, J = 7.7 Hz, 2H), 4.22 (t, J = 
6.5 Hz, 2H), 2.50 (s, 3H), 2.15 – 2.02 (m, 2H), 1.73 (p, J = 6.9 Hz, 2H), 1.42 – 1.25 (m, 
20H). 13C NMR (75 MHz, CD3OD) δ 169.0, 162.2, 150.2, 149.0, 144.1, 139.4, 137.3, 
134.1, 132.1, 131.7, 131.4, 123.0, 121.6, 119.6, 119.2, 113.6, 65.5, 59.4, 31.1, 30.6, 
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30.54, 30.47, 30.4, 30.2, 30.1, 29.8, 27.4, 27.1, 22.5. LRMS (ESI+) m/z 476 (M)+. 
HRMS (ESI+) m/z 476.3165 (C31H42NO3 requires 476.3165). 
 (14-(4-Formyl-3-hydroxyphenoxy)tetradecyl)triphenylphosphonium bromide (30). 
Following the general procedure 5.1.2.1 the reaction mixture was heated at 80 ºC for 10 
days. The solvent was removed under vacuum and 30 was obtained as colorless solid 
(25.5 mg, 71%) by recrystallization from CH2Cl2/EtOAc; mp 82 – 94 ºC. HPLC (UV) > 
95 %. 1H NMR (500 MHz, CD3OD) δ 9.77 (s, 1H), 7.92 – 7.86 (m, 3H), 7.83 – 7.73 (m, 
12H), 7.57 (d, J = 8.7 Hz, 1H), 6.57 (dd, J = 2.4, 8.7 Hz, 1H), 6.42 (d, J = 2.4 Hz, 1H), 
4.04 (t, J = 6.4 Hz, 2H), 3.42 – 3.35 (m, 2H), 1.82 – 1.74 (m, 2H), 1.71 – 1.61 (m, 2H), 
1.54 (p, J = 7.3 Hz, 2H), 1.50 – 1.43 (m, 2H), 1.41 – 1.21 (m, 16H). 13C NMR (75 MHz, 
CD3OD) δ 195.6, 167.9, 165.4, 136.3 (d, J= 3.2 Hz), 136.2, 134.8 (d, J= 10.0 Hz), 131.5 
(d, J= 12.7 Hz), 120.0 (d, J= 86.6 Hz), 116.8, 109.3, 102.0, 69.6, 31.6 (d, J= 16.2 Hz), 
30.7, 30.6, 30.5, 30.4, 30.35, 30.1, 29.9, 27.0, 23.5 (d, J= 4.3 Hz), 22.7 (d, J= 50.8 Hz). 
LRMS (ESI+) m/z 595 (M)+. HRMS (ESI+) m/z 595.3346 (C39H48O3P requires 
595.3341).
 
1-(14-(4-Formyl-3-hydroxyphenoxy)tetradecyl)quinolin-1-ium bromide (31). 
Following the general procedure 5.1.2.2 the reaction mixture was heated at 80 ºC for 10 
days. The solvent was removed under vacuum and 31 was obtained as beige solid (10 
mg, 36%) by recrystallization from CH2Cl2/EtOAc; mp 118 – 122 ºC. HPLC (UV) > 95 
%. 1H NMR (300 MHz, CD3OD) δ 9.77 (s, 1H), 9.46 – 9.42 (m, 1H), 9.22 (d, J = 8.3 
Hz, 1H), 8.57 (d, J = 9.0 Hz, 1H), 8.44 (dd, J = 8.3, 1.5 Hz, 1H), 8.30 (ddd, J = 8.8, 7.0, 
1.5 Hz, 1H), 8.14 – 8.02 (m, 2H), 7.56 (d, J = 8.7 Hz, 1H), 6.57 (dd, J = 8.7, 2.4 Hz, 
1H), 6.41 (d, J = 2.4 Hz, 1H), 5.11 (t, J = 9.3 Hz, 2H), 4.04 (t, J = 6.4 Hz, 2H), 1.78 (p, 
J = 6.7 Hz, 2H), 1.56 – 1.29 (m, 22H). 13C NMR (75 MHz, CD3OD) δ 195.6, 167.9, 
165.4, 150.3, 149.0, 139.4, 137.3, 136.1, 132.2, 131.8, 131.4, 123.0, 119.7, 116.7, 
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109.3, 102.0, 69.6, 59.4, 31.14, 31.13, 30.6, 30.5, 30.4, 30.2, 30.1, 27.5, 27.0, 24.2. 
LRMS (ESI+) m/z 462 (M)+. HRMS (ESI+) m/z 462.3010 (C30H40NO3 requires 
462.3008).
 
 
5.2. Biology 
5.2.1. Test Organisms and culture media. Three strains of Trypanosoma brucei 
(bloodstream form, BSF) were used in this study: (1) Wild type strain Trypanosoma 
brucei brucei Lister 427 (427-WT) [35]; (2) A multi-drug resistant strain, B48, which 
was created from 427-WT after deletion of the TbAT1 drug transporter [36] followed 
by adaptation to increasing concentrations to pentamidine [19]; (3) A 427-WT-derived 
clone, TbAOX, generated by transfecting the wild-type cells with the vector pHD1336 
[37] containing the TAO gene, exactly as described for the expression of TbAT1 [38].  
All T. b. brucei strains were used as bloodstream trypomastigotes, and cultured in 
standard HMI-9 medium, supplemented with 10% heat inactivated fetal bovine serum 
(FBS), 14 µL β-mercaptoethanol, and 3.0 g/L NaHCO3 (pH 7.4). Parasites were 
cultured in vented flasks at 37 ºC in a 5% CO2 atmosphere and were passaged every 3 
days. Bloodstream forms of the T. congolense savannah-type strain IL3000 were 
cultured exactly as described by Coustou et al [39]; the strain was kindly provided by 
Theo Baltz (Université Victor Segalen Bordeaux 2, Bordeaux, France). 
5.2.2. Drug susceptibility assays. The drug susceptibilities of bloodstream form 
trypanosomes T. b. brucei s427 and B48 were determined using the resazurin assay as 
previously described [40, 41], with slight modifications. The assays were performed in 
96-well plates with of 2×104 cells/well for T. brucei and 5×104 cells/well for T. 
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congolense. Trypanosomes and test drugs were incubated for a period of 48 hours 
followed by the addition of 20 µL of Alamar Blue solution (125 mg/L resazurin sodium 
salt (Sigma-Aldrich) in phosphate buffered saline (PBS), followed by a further 24 h 
incubation. Four trypanocides were used as positive controls including: pentamidine, 
diminazene aceturate, salicylic hydroxamic acid (SHAM), and phenylarsine oxide 
(PAO) (all from Sigma-Aldrich). Fluorescence was measured using a FLUOstar Optima 
(BMG Labtech, Durham, NC, USA) at wavelengths of 544 nm for excitation, 590 for 
emission. EC50 values were calculated by non-linear regression using an equation for a 
sigmoidal dose-response curve with variable slope using Prism 5.0 (GraphPad Software 
Inc., San Diego, CA, USA). In vitro assays against T. b. rhodesiense STIB900 
(compounds 15 and 16) were performed as described previously [42]. 
5.2.3. Cytotoxicity assay using Human Embryonic Kidney (HEK)/ Human 
Foreskin Fibroblast (HFF) 293-T cells. Toxicity of drugs to mammalian cells was 
carried out in mammalian cell lines according to a method previously described [43], 
with slight modifications. Briefly, HEK or HFF cells were grown in a culture containing 
500 mL Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma), 50 mL New-born 
Calf Serum (NBCS) (Gibco), 5 mL Penicillin/Streptomycin (Gibco) and 5 mL L-
Glutamax (200 mM, Gibco). Mammalian cells were incubated at 37 ºC/5% CO2 and 
were passaged when they reached 80-85% confluence in vented flasks. For the assay, 
cells were suspended at a density of 3×105 cells/mL, of which 100 µL was added to each 
well of a 96-well plate. The plate was incubated at 37 ºC/5% CO2 for 24 h to allow cell 
adhesion. Serial drug dilutions were prepared in a separate sterile plate and 100 µL was 
transferred to the wells containing the cells; PAO was used as positive control. The 
plate was then incubated at 37 ºC/5% CO2 for an additional period of 30 h followed by 
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the addition of 10 µL of resazurin solution (125 mg/L in PBS) and a final incubation at 
37 ºC/5% CO2 for 24 h. The plate was read in a FLUOstar OPTIMA fluorimeter at 
wavelengths 530 nm for excitation and 590 nm for emission. The data were analyzed 
using GraphPad Prism 5.0 to determine EC50 values. The selectivity index was 
calculated as EC50 (HEK) / EC50 (Trypanosoma). 
5.2.4. Cloning and expression of physiologic Trypanosome Alternative Oxidase 
(∆MTS-TAO). The pET SUMO expression system (Thermo Fisher Scientific) was 
used for the cloning of ∆MTS-TAO. After expression in the heme-deficient FN102 E. 
coli, the 11 kD SUMO moiety was cleaved off by the ULP-1 (Ubiquitin-like-specific 
protease 1) protease at the carboxyl terminal, producing the native TAO protein. TA 
cloning technology (Thermo Fisher Scientific) was used following the manufacturer’s 
instructions. The technique depends on the ability of adenine (A) and thymine (T) on 
different DNA fragments to hybridize and become bonded in the presence of a ligase 
(the T4 ligase was used in this experiment). PCR products were amplified using Taq 
DNA polymerase, which adds an adenine to the 3' end of the PCR product. The PCR-
amplified insert was then cloned into pET101-NHis6SUMO, which is a linearized 
vector having a complementary 3' thymine (T) overhang. 
5.2.5. Plasmid construction for recombinant TAO expression. A previous construct, 
the pTAO plasmid, containing the cDNA for TAO from T. brucei brucei TC221 as 
previously described by Nihei et al.,[44] was used as template for the amplification of 
TAO using 5’-AGCCGTAACCACGCATCGAGG-3’ and 5’-
CTTGTTGAAGCAGAGAATGAGCGC-3’ as sense and antisense cloning primers, 
respectively, for full length TAO, while a 5’-
AGCGACGCCAAAACACCTGTGTGGG-3’ and 5’-
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CTTGTTGAAGCAGAGAATGAGCGC-3’ primer pair was used to amplify the gene 
segment without the MTS coding sequence (∆MTS-TAO). Pfu Ultra II Fusion HS DNA 
polymerase (Stratagene) was used for the initial PCR amplifications followed by Taq 
DNA polymerase for addition of a 3’-A overhang. Following the manufacturer’s 
procedure, gel-purified PCR product (TAO) containing the 3’-A overhang was inserted 
into pET-SUMO Expression plasmid vector (Thermo Fisher), and used for the chemical 
transformation of One Shot TOP10 E. coli cells (Thermo Fisher). Transformants 
colonies were then grown on 50 µg/mL kanamycin-supplemented Luria-Broth (LB) 
plates. Construct-positive clones were confirmed by colony PCR and were then selected 
for liquid culture in LB media for the amplification of vector construct. The TOYOBO 
MagExtractor kit (Osaka, Japan) was used for extraction of plasmids, which were 
subjected to further confirmation by sequence analysis. The NHis6SUMO-tagged TAO 
was further subcloned into pET101 (Invitrogen), which contains a carbenicillin-
resistance cassette. Following PCR and gene analyses, the correct construct was used to 
transform a heme-deficient E. coli FN102 host with a kanamycin resistance gene. The 
construct-positive colonies were selected under carbenicillin and kanamycin pressure, 
and selected for storage and expression experiments.  
5.2.6. Preparation of inner membrane-rich fraction. Membrane samples were 
prepared as described by Kido et al. [14] with some modification. Briefly, glycerol 
stock of a NHis6SUMO-TAO-pET101/FN102 colony was streaked onto a LB plate 
containing 100 µg/mL carbenicillin, 50 µg/mL kanamycin, and 50 µg/mL 
aminolevulinic acid (ALA) using a sterilized platinum rod spreader, which were then 
incubated at 37 °C overnight. From the many colonies that appeared, a single colony of 
the strain carrying the cDNA for T. b. brucei full-length or ∆MTS-TAO was used to 
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prepare a pre-culture in 100 mL of Luria Broth medium containing 10 mg carbenicillin, 
5 mg kanamycin, and 5 mg ALA for 6 h at 37 °C in a shaking incubator set at 250 rpm. 
When the OD600 was 0.6, the pre-culture was transferred to centrifuge tubes and 
centrifuged at 8000 rpm for 3 minutes at 4 °C. The supernatant was discarded and the 
pellets were re-suspended with 20 mL of fresh culture media, and then centrifuged at 
8000 rpm at 4 °C for 3 minutes. This wash process was repeated 2 more times to 
remove residual 5-aminolevulinic acid in the pellets. The pellets were resuspended and 
aerobically grown at 30 °C in a total volume of 6 L of S-medium containing, 0.2% 
(w/v) glucose, 50 g tryptone peptone, 25 casamino acid, 25 g yeast extract, 15 g 
KH2PO4, 52 g K2HPO4, 12.5 g (NH4)2SO4, 3.25 g trisodium-citrate.2H2O, 0.25 g 
MgSO4·7H2O, 0.125 g FeCl3, 0.125 g FeSO4·7H2O, and 0.5 g carbenicillin, and 0.25 g 
kanamycin, dispensed into 10 flasks for maximum aeration. The initial OD600 of the 
culture was 0.02. Expression of soluble and active TAO was made possible by induction 
with 25 µM of the inducer, isopropyl β-D-thiogalactopyranoside (IPTG) when optical 
density at 600 nm (OD600) reached 0.3; post-induction growth was for 12 h at 20 °C. 
The cells were harvested by centrifugation at 8000 rpm at 4 ºC for 5 minutes. Pellets 
were re-suspended in 50 mM Tris-HCl (pH 7.5) containing 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich), 40% (w/w) sucrose, and a 
protease inhibitor cocktail (Sigma). The cells were broken by a French press with 
pressure between 150 and 200 megapascal. Unbroken cells were removed by 
centrifugation at 8000×g for 10 min in a Beckman Optima L-90K ultracentrifuge 
(USA). Inner membranes of NHis6SUMO-TAO-pET101/FN102 cells were fractionated 
in 40% sucrose by ultracentrifugation at 200,000×g for 1 h at 4 °C in a Beckman 
Optima L-90K (30 mL of 20% sucrose lysate was overlaid on 30 mL of 50 mM Tris-
HCl pH 7.5 containing 40% (w/w) sucrose per ultracentrifuge tube). The buoyant rich 
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inner membranes were transferred to a fresh centrifugation tube, and a pellet of inner 
membranes was obtained by a further ultracentrifugation step at 200,000×g for 1 h 
(Beckman Optima L-90K, USA). The resulting brown-colored inner membrane pellet 
was re-suspended in 1.5 mL 50 mM Tris-HCl (pH 7.5) containing 20% (w/w) sucrose. 
5.2.7. Membrane solubilisation. The inner membranes were resuspended with 
solubilisation buffer (6 mg/mL protein in 50 mM Tris–HCl, 14% (w/v) n-octyl-β-D-
glucopyranoside (OG), 2 M MgSO4.7H2O, 20 % (v/v) glycerol, pH 7.3) at 4 °C (in the 
cold room). The membrane sample was maintained at 4 ºC throughout the solubilization 
process. The solubilized membranes were ultracentrifuged at 42,000 rpm for 1 h at 4 °C. 
The total protein, quinol oxidase activities of the samples at various stages (i.e. before 
centrifugation, supernatant and pellet) were determined. 
5.2.8. Purification of rTAO (fl and ∆MTS). Purified rTAO was obtained by means of 
a hybrid batch/column procedure using TALON metal affinity resin (Clontech, 
Mountain View, USA) containing Co2+ metal ion which has a strong affinity for the 
histidine tag on SUMO-TAO, according to the manufacturer's instructions and exactly 
as described previously for fl-rTAO [14].  
5.2.9. Ubiquinol oxidase/TAO inhibition assay. The Ubiquinol oxidase activity of 
purified TAO was measured by recording the change in absorbance of ubiquinol-1, at 
278 nm, on a double beam-dual wavelength spectrophotometer (Shimadzu UV-3000) 
over 2 minutes. Reactions were initiated by the addition of ubiquinol-1 (ε278=15,000 
M−1 cm−1) after 2 min of pre-incubation at 25 °C in the presence of ∆MTS-TAO and 50 
mM Tris-HCl (pH 7.4) in a total reaction volume of 1 mL. For TAO kinetics/inhibitor 
assays, the reaction was initiated by the addition of varying concentrations of ubiquinol-
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1 after 2 min of pre-incubation at 25 °C in the presence of fixed amounts of ∆MTS-
TAO and varying concentrations of the inhibitor, all in a 50 mM Tris-HCl (pH 7.4) 
buffer containing 0.05% (w/v) octaethylene glycol-monododecylether detergent. 
The inhibitors were dissolved in DMSO to make a stock solution of 10 mM, which was 
stored at -20 ºC and used for the assay. The known TAO inhibitors ascofuranone and 
salicylhydroxamic acid (SHAM) were used as positive controls in the assay while an 
equal volume of DMSO was used as negative control. The DMSO had no effect on 
TAO activity (result not shown). Auto-oxidation of Ubiquinol-1 was determined as a 
control, using the same protocol but without TAO; none was observed. The purity of 
∆MTS-TAO was tested in the presence of up to 1 mM ascofuranone (0, 0.01, 0.1, 1.0, 
10.0 µM and 1 mM).  
5.2.10. Chemicals. All chemicals were of analytical grade. Ubiquinone-1 and protease 
inhibitor cocktail were purchased from Sigma-Aldrich.; detergents were purchased from 
Dojindo Molecular Technologies Inc. (Kumamoto, Japan).  
5.2.11. In vivo activity. T. b. rhodesiense (STIB900/luc) acute mouse model. The 
STIB900_luc acute mouse model mimics the first stage of the disease. T. b. rhodesiense 
parasites were genetically modified with pTb-AMluc construct [34] kindly provided by 
JM Kelly, containing red-shifted luciferase reporter gene (PpyRE9h). This genetically 
modified strain of T. b. rhodesiense transfected with a red-shifted luciferase gene allows 
monitoring of the parasitaemia by live imaging. Four female NMRI mice were used per 
experimental group. Heparinized blood from a donor mouse with approximately 5×106 
/mL parasitaemia was suspended in PSG to obtain a trypanosome suspension of 1×105 
/mL. Each mouse was inoculated i.p. with 104 bloodstream forms of STIB900/luc, 
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respectively. Compounds 15 and 16 were formulated in 100% DMSO and diluted 10-
fold in distilled water. Compound treatment was initiated 3 days post-infection on four 
consecutive days in a volume of 0.1 mL/10 g (final concentration = 10 mg/kg). Three 
mice served as infected-untreated controls. They were not injected with the vehicle 
alone since we have established in our laboratory that these vehicles do not affect 
parasitaemia nor the mice (data not shown). Parasitaemia was monitored by whole-
animal live imaging the day after the last treatment (day 7) and 3 days after treatment 
(day 10). The experiment was stopped on day 10 because parasitaemia relapse was 
detected in all the treated mice. For imaging, mice were inoculated i.p. with 200 µL D-
luciferin (15 mg/mL in PBS) (Perkin Elmer), and 10 minutes later anaesthetised with 
2.5% isofluorane. Light emission was recorded for 5 minutes using in vivo imaging 
systems (IVIS) (Perkin Elmer). Mice are considered cured if the bioluminescence signal 
at day 60 post-infection is not higher than the background level. In vivo efficacy studies 
in mice were conducted at the Swiss Tropical and Public Health Institute (Basel) 
(License number 2813) according to the rules and regulations for the protection of 
animal rights ("Tierschutzverordnung") of the Swiss "Bundesamt für Veterinärwesen". 
They were approved by the veterinary office of Canton Basel-Stadt, Switzerland. 
5.3. Stability assessment of the inhibitors 
5.3.1. Metabolic stability in serum. An adaptation of the protocol by L. Di et al was 
followed [25]. Stock solutions (2 mM in DMSO) of compounds 3, 15, 16, 19, 20, 30 
and ditialzem were prepared. For each test compound, 195 µL of a 50/50 (v/v) solution 
of sterile filtered mouse serum (Aldrich M6906) or horse serum (Sigma H-1270) in 
phosphate-buffered saline (PBS pH 7.4, isotonic) was dispensed in 6 Eppendorf tubes 
and the tubes were pre-incubated at 37 ºC for 15 min. The test compounds (5 µL of 
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stock solution) were added, and the sample was vortexed and incubated at 37 ºC at six 
different time points (0, 0.25, 0.5, 1, 2 and 24 h) with the serum. For each time point, 
the initiation of the reaction was staggered so all incubation times were terminated at the 
same time by addition of 600 µL of cold acetonitrile. For the time 0, the reaction was 
quenched with ice-cold acetonitrile right after mixing with serum. The tubes were 
vortexed and centrifuged at 4000 rpm for 15 min. The supernatant (600 µL) was 
transferred to 2 mL HPLC vials and 200 µL of 1.67 mM 2,5-dihydroxybenzoic acid 
(internal standard) in acetonitrile was added to each HPLC sample for LC–MS analysis. 
HPLC analysis was performed with a SunFire C18-2.1 µm column (4.6 mm × 50 mm); 
injection: 2 µL, flow rate: 0.35 mL/min, detection at 254 nm (ditialzem, 13, 15 and 19) 
and 316 nm (3, 16, 20 and 30). 
5.3.2. Microsomal stability. Microsomal stability of compounds 15 and 16 toward 
metabolism by cytochrome P450 (Phase-I metabolism) and Uridine diphosphate 
Glucuronosyl-Transfererase (UGT) (Phase-II metabolism) was studied in presence of 
NADPH and UDPGA, respectively. Incubation media (0.6 mL of final reaction volume) 
containing 0.8 mg/mL protein of human liver microsomes (HLM) (Gentest; Corning) or 
1 mg/mL protein of human liver S9 fraction (Sigma-Aldrich) in 80 mM potassium 
phosphate buffer (pH 7.4) and 15, 16 or diclofenac in 5 µM concentration were added 
with NADPH (1 mM), and incubated in a water bath at 37 ºC for 2 h.  Alternatively, 
incubation media (0.6 mL of final reaction volume) containing human liver S9 mix 
fraction (1 mg/mL protein) in 80 mM potassium phosphate buffer (pH 7.4) with 15 or 
16 in 5 µM concentration were added with UDPGA (2 mM), and incubated at 37 ºC for 
2 h. Aliquots (100 µL) were withdrawn at 0, 15, 30, 60 and 120 min, added to 100 µL of 
acetonitrile, vortexed and centrifuged at 10000 rpm. An aliquot of supernatant (20 µL) 
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was analyzed by RP-HPLC (Agilent 1200 apparatus with a 1100 diode array detector 
(DAD) and a 1046A fluorescence detector) using a reversed phase 3.9 × 150 mm, 4 µm, 
Nova-pak C18 column (Waters, Milford, MA, USA) under the following 
chromatographic conditions: eluent A: 50 mM ammonium phosphate buffer (pH 3) and 
eluent B: 20 % A in acetonitrile.  A linear gradient was used from 0 to 100% B in 8 
min, and then 100% B for 10 min.  Under these conditions 15 and 16 eluted at 12.8 and 
10.5 min, respectively. 15 was determined at 230 and 265 nm, 16 at 237 nm and by 
fluorescence (237 nm, excitation and 400 nm, emission) and diclofenac at 280 nm.  
Assays were carried out at least in duplicate. Concentration of DMSO was <0.25%. 
5.4. Molecular modeling of TAO-inhibitor complexes 
The binding mode of TAO and SHAM derivatives was predicted by structural 
modelling using the TAO-AF2779-OH complex structure (PDB ID, 3AAV) [26] as a 
template. AF2779-OH is an ascofuranone (AF) derivative comprised of a substituted 
aromatic head and an isoprenoid tail. In the TAO-AF2779-OH structure, the inhibitor 
was bound tightly in the active site cavity with its aromatic head oriented towards the 
essential di-iron center, and its tail projecting out of the cavity [26]. For the modelling, 
the aromatic head of compounds 5, 13, 14, 17, 19, 20, and 28 was superposed on the 
head portion of the AF2779-OH using the coot program [45]. The model structure was 
subjected to 200 steps of energy minimization in order to avoid disallowed contacts, 
using the CNS software [46]. The models with the lowest energy scores (structurally 
most favorable binding pattern) were selected. 
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Figures S1–S5. Table S1-S3. Method for SDS-PAGE of TAO. Preparation of 
Ubiquinol-1 (UQ1H2) from Ubiquinone-1 (UQ1). 1H and 13C NMR spectra for 14, 15, 
16, 28, 30, and 31. 
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Abbreviations used 
AF, ascofuranone; ALA, aminolevulinic acid; AOX, alternative oxidase; BSF 
trypanosome, bloodstream form trypanosome; 2,4-DHBA, 2,4-dihydroxybenzoic acid; 
GK, glycerol kinase; G3P, glycerol 3-phosphate; HB, hydrogen bond; HAT, human 
African trypanosomiasis; HFF cells, human foreskin fibroblast cells; LC, lipophilic 
cation; MTS, mitochondrial targeting signal; PAO, phenylarsine oxide; RF, resistance 
factor; SHAM, salicylhydroxamic acid; SI, selectivity index; SPR, surface plasmon 
resonance; SUMO, small ubiquitin-related modifier; TAO, trypanosome alternative 
oxidase; TPP, triphenylphosphonium; SI, selectivity index.  
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Highlights 
• The physiologically relevant ∆MTS-TAO was expressed and purified for the 
first time. 
• Nanomolar range inhibitors of ∆MTS-TAO were discovered.  
• The inhibitors displayed nanomolar range EC50 values against WT and drug-
resistant strains of T. brucei and T. congolense. 
• Compounds’ metabolic stability in liver microsomes and mouse serum was 
studied. 
• Compounds 15 and 16 showed in vivo activity against T. b. rhodesiense. 
